DE10042058A1 - Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation - Google Patents
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparationInfo
- Publication number
- DE10042058A1 DE10042058A1 DE10042058A DE10042058A DE10042058A1 DE 10042058 A1 DE10042058 A1 DE 10042058A1 DE 10042058 A DE10042058 A DE 10042058A DE 10042058 A DE10042058 A DE 10042058A DE 10042058 A1 DE10042058 A1 DE 10042058A1
- Authority
- DE
- Germany
- Prior art keywords
- amino
- phenyl
- quinazoline
- chloro
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Description
Gegenstand der vorliegenden Erfindung sind bicyclische Hetero
cyclen der allgemeinen Formel
The present invention relates to bicyclic heterocycles of the general formula
deren Tautomeren, deren Stereoisomere und deren Salze, insbe sonders deren physiologisch verträgliche Salze mit anorgani schen oder organischen Säuren oder Basen, welche wertvolle pharmakologische Eigenschaften aufweisen, insbesondere eine Hemmwirkung auf die durch Tyrosinkinasen vermittelte Signal transduktion, deren Verwendung zur Behandlung von Krankheiten, insbesondere von Tumorerkrankungen, von Erkrankungen der Lunge und der Atemwege und deren Herstellung.their tautomers, their stereoisomers and their salts, esp especially their physiologically acceptable salts with anorgani or organic acids or bases, which valuable have pharmacological properties, in particular a Inhibitory effect on tyrosine kinase mediated signal transduction, their use for the treatment of diseases, in particular of tumor diseases, diseases of the lung and the respiratory tract and their production.
In der obigen allgemeinen Formel I bedeutet
Ra eine Benzyl- oder 1-Phenylethylgruppe oder eine durch die
Reste R1 und R2 substituierte Phenylgruppe, wobei
R1 ein Wasserstoff-, Fluor-, Chlor- oder Bromatom, eine
Methyl-, Trifluormethyl-, Cyan- oder Ethinylgruppe und
R2 ein Wasserstoff- oder Fluoratom darstellen,
einer der Reste Rb oder Rc eine R3-(CH2)m-O-Gruppe und der andere
der Reste Rb oder Rc eine Methoxy-, Cyclobutyloxy-, Cyclopenty
loxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclopen
tylmethoxygruppe, wobei
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylamino- oder
-N-(2-Oxo-tetrahydrofuran-4-yl)-ethylaminogruppe,
eine an den Methylengruppen durch eine oder zwei Methyl-
oder Ethylgruppen substituierte R4-O-CO-CH2-N-CH2CH2-OH-
Gruppe, in der
R4 ein Wasserstoffatom oder eine C1-4-Alkylgruppe
darstellt,
oder eine durch eine oder zwei Methyl- oder Ethylgruppen
substituierte 2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
mit der Maßgabe, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-(2-{N-(2-hydroxy-2-methyl-prop-1-yl)-N-[(ethoxycarbonyl)-
methyl]-amino}-ethoxy)-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin-
4-yl)-ethoxy]-7-methoxy-chinazolin und
4-[(3-Brom-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-
N-methyl-amino]-ethoxy}-7-methoxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.
In the above general formula I means
R a represents a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R 1 and R 2 , where
R 1 is a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyano or ethynyl group and
R 2 represents a hydrogen or fluorine atom,
one of the radicals R b or R c is an R 3 - (CH 2 ) m -O group and the other of the radicals R b or R c is a methoxy, cyclobutyloxy, cyclopenty loxy, cyclopropylmethoxy, cyclobutylmethoxy or Cyclopen tylmethoxygruppe , in which
R 3 is an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino or -N- (2-oxo-tetrahydrofuran-4-yl) -ethylamino group,
a R 4 -O-CO-CH 2 -N-CH 2 CH 2 -OH group substituted on the methylene groups by one or two methyl or ethyl groups, in which
R 4 represents a hydrogen atom or a C 1-4 alkyl group,
or a substituted by one or two methyl or ethyl groups 2-oxo-morpholin-4-yl group and
m represent the number 2 or 3,
with the proviso that the connections
4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl ) - methyl] -amino} -ethoxy) -quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline and
4 - [(3-Bromo-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7-methoxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Bevorzugte Verbindungen der obigen allgemeinen Formel I sind
diejenigen, in denen
Ra eine Benzyl- oder 1-Phenylethylgruppe oder eine durch die
Reste R1 und R2 substituierte Phenylgruppe, wobei
R1 ein Wasserstoff-, Fluor-, Chlor- oder Bromatom, eine
Methyl-, Trifluormethyl-, Cyan- oder Ethinylgruppe und
R2 ein Wasserstoff- oder Fluoratom darstellen,
einer der Reste Rb oder Rc eine R3-(CH2)m-O-Gruppe und der andere
der Reste Rb oder Rc eine Methoxy-, Cyclobutyloxy-,
Cyclopentyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder
Cyclopentylmethoxygruppe, wobei
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylamino- oder
N-(2-Oxo-tetrahydrofuran-4-yl)-ethylaminogruppe,
eine an den Methylengruppen durch eine oder zwei Methyl-
oder Ethylgruppen substituierte R4-O-CO-CH2-N-CH2CH2-OH-
Gruppe, in der
R4 ein Wasserstoffatom oder eine C1-4-Alkylgruppe
darstellt,
oder eine durch eine oder zwei Methyl- oder Ethylgruppen
substituierte 2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-(2-{N-(2-hydroxy-2-methyl-prop-1-yl)-N-[(ethoxycarbonyl)-
methyl]-amino}-ethoxy)-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin-
4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-
N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-(2-{N-(2-hydroxy-2-methyl-prop-
1-yl)-N-[(ethoxycarbonyl)methyl]-amino}-ethoxy)-7-methoxy-
chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(3-methyl-2-oxo-morpholin-
4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(5,5-dimethyl-2-oxo-morpholin-
4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentyloxy-china
zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentylmethoxy-
chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-cyclopentylmethoxy-chinazolin,
(R)-4-[(1-Phenyl-ethyl)amino]-6-[3-(6,6-dimethyl-2-oxo-morpho
lin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentyloxy-china
zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentylmethoxy-
chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-cyclopentylmethoxy-chinazolin und
(R)-4-[(1-Phenyl-ethyl)amino]-7-[3-(6,6-dimethyl-2-oxo-morpho
lin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin
ausgeschlossen sind,
insbesondere diejenigen, in denen
Ra eine 1-Phenylethylgruppe oder eine durch die Reste R1 und R2
substituierte Phenylgruppe darstellt, wobei
R1 ein Fluor-, Chlor- oder Bromatom, eine Methyl- oder
Ethinylgruppe und
R2 ein Wasserstoff- oder Fluoratom darstellen,
einer der Reste Rb oder Rc eine R3-(CH2)m-O-Gruppe und der andere
der Reste Rb oder Rc eine Methoxy-, Cyclobutyloxy-, Cyclo
pentyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder
Cyclopentylmethoxygruppe, wobei
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylaminogruppe,
eine an den Methylengruppen durch eine oder zwei Methyl
gruppen substituierte R4-O-CO-CH2-N-CH2CH2-OH-Gruppe, in der
R4 eine C1-4-Alkylgruppe darstellt,
oder eine durch eine oder zwei Methylgruppen substituierte
2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-(2-{N-(2-hydroxy-2-methyl-prop-1-yl)-N-[(ethoxycarbonyl)-
methyl]-amino}-ethoxy)-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin-
4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-
N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-(2-{N-(2-hydroxy-2-methyl-prop-
1-yl)-N-[(ethoxycarbonyl)methyl]-amino}-ethoxy)-7-methoxy-
chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(3-methyl-2-oxo-morpholin-
4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(5,5-dimethyl-2-oxo-morpholin-
4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentyloxy-china
zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentylmethoxy-
chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-cyclopentylmethoxy-chinazolin,
(R)-4-[(1-Phenyl-ethyl)amino]-6-[3-(6,6-dimethyl-2-oxo-mor
pholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentyloxy-china
zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentylmethoxy-
chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-1)-propyloxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-cyclopentylmethoxy-chinazolin und
(R)-4-[(1-Phenyl-ethyl)amino]-7-[3-(6,6-dimethyl-2-oxo-mor
pholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.Preferred compounds of the above general formula I are those in which
R a represents a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R 1 and R 2 , where
R 1 is a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyano or ethynyl group and
R 2 represents a hydrogen or fluorine atom,
one of R b or R c is an R 3 - (CH 2 ) m -O group and the other of R b or R c is a methoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group, wherein
R 3 is an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino or N- (2-oxo-tetrahydrofuran-4-yl) -ethylamino group,
a R 4 -O-CO-CH 2 -N-CH 2 CH 2 -OH group substituted on the methylene groups by one or two methyl or ethyl groups, in which
R 4 represents a hydrogen atom or a C 1-4 alkyl group,
or a substituted by one or two methyl or ethyl groups 2-oxo-morpholin-4-yl group and
m represent the number 2 or 3,
with the proviso mean that the connections
4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl ) - methyl] -amino} -ethoxy) -quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxo) morpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl) -methyl] -amino} -ethoxy ) -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentylmethoxy-quinazoline,
(R) -4 - [(1-phenyl-ethyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentylmethoxy-quinazoline and
(R) -4 - [(1-phenyl-ethyl) -amino] -7- [3- (6,6-dimethyl-2-oxo-morpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline
excluded are,
especially those in which
R a represents a 1-phenylethyl group or a phenyl group substituted by the radicals R 1 and R 2 , wherein
R 1 is a fluorine, chlorine or bromine atom, a methyl or ethynyl group and
R 2 represents a hydrogen or fluorine atom,
one of R b or R c is an R 3 - (CH 2 ) m -O group and the other of R b or R c is a methoxy, cyclobutyloxy, cyclo pentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group, in which
R 3 is an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino group,
a substituted on the methylene groups by one or two methyl groups R 4 -O-CO-CH 2 -N-CH 2 CH 2 -OH group, in which
R 4 represents a C 1-4 alkyl group,
or a substituted by one or two methyl groups 2-oxo-morpholin-4-yl group and
m represent the number 2 or 3,
with the proviso mean that the connections
4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl ) - methyl] -amino} -ethoxy) -quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl) -methyl] -amino} -ethoxy ) -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentylmethoxy-quinazoline,
(R) -4 - [(1-phenyl-ethyl) amino] -6- [3- (6,6-dimethyl-2-oxo-morpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholine-4-1) -propyloxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentylmethoxy-quinazoline and
(R) -4 - [(1-Phenylethyl) amino] -7- [3- (6,6-dimethyl-2-oxo-morpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Besonders bevorzugte Verbindungen der allgemeinen Formel I
sind diejenigen, in denen
Ra eine 1-Phenylethylgruppe oder eine durch die Reste R1 und R2
substituierte Phenylgruppe darstellt, wobei
R1 ein Fluor-, Chlor- oder Bromatom und
R2 ein Wasserstoff- oder Fluoratom darstellen,
einer der Reste Rb oder Rc eine R3-(CH2)m-O-Gruppe und der andere
der Reste Rb oder Rc eine Methoxy-, Cyclobutyloxy-, Cyclopen
tyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclo
pentylmethoxygruppe, wobei
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylaminogruppe
oder eine durch eine oder zwei Methylgruppen substituierte
2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin-
4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-
N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(3-methyl-2-oxo-morpholin-4-yl)-
ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(5,5-dimethyl-2-oxo-morpholin-
4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentyloxy-china
zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofu
ran-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentylmethoxy-china
zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-cyclopentylmethoxy-chinazolin,
(R)-4-[(1-Phenyl-ethyl)amino]-6-[3-(6,6-dimethyl-2-oxo-mor
pholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentyloxy-china
zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentylmethoxy-
chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-cyclopentylmethoxy-chinazolin und
(R)-4-[(1-Phenyl-ethyl)amino]-7-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.Particularly preferred compounds of general formula I are those in which
R a represents a 1-phenylethyl group or a phenyl group substituted by the radicals R 1 and R 2 , wherein
R 1 is a fluorine, chlorine or bromine atom and
R 2 represents a hydrogen or fluorine atom,
one of the radicals R b or R c is an R 3 - (CH 2 ) m -O group and the other of the radicals R b or R c is a methoxy, cyclobutyloxy, Cyclopen tyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclo pentylmethoxy , in which
R 3 represents an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino group or a 2-oxo-morpholin-4-yl group substituted by one or two methyl groups and
m represent the number 2 or 3,
with the proviso mean that the connections
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentylmethoxy-china zoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentylmethoxy-quinazoline,
(R) -4 - [(1-phenyl-ethyl) amino] -6- [3- (6,6-dimethyl-2-oxo-morpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentylmethoxy-quinazoline and
(R) -4 - [(1-Phenylethyl) amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Ganz besonders bevorzugte Verbindungen der allgemeinen Formel
I sind diejenigen, in denen
Ra eine 1-Phenylethyl-, 3-Bromphenyl- oder 3-Chlor-4-fluor
phenylgruppe,
Rb eine R3-(CH2)m-O-Gruppe, in der
R3 eine durch eine oder zwei Methylgruppen substituierte
2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
und Rc eine Methoxy-, Cyclobutyloxy- oder Cyclopropylmethoxy
gruppe mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin-
4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(3-methyl-2-oxo-morpholin-
4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(5,5-dimethyl-2-oxo-morpholin-
4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-cyclopropylmethoxy-chinazolin und
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.Very particularly preferred compounds of general formula I are those in which
R a represents a 1-phenylethyl, 3-bromophenyl or 3-chloro-4-fluorophenyl group,
R b is an R 3 - (CH 2 ) m -O- group in which
R 3 is a substituted by one or two methyl groups 2-oxo-morpholin-4-yl group and
m represent the number 2 or 3,
and R c is a methoxy, cyclobutyloxy or cyclopropylmethoxy group with the proviso that the compounds
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopropylmethoxy-quinazoline and
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-methoxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Ganz besonders bevorzugte Verbindungen der allgemeinen Formel
I sind auch diejenigen, in denen
Ra eine 3-Chlor-4-fluor-phenylgruppe,
Rb eine Cyclopentyloxy-, Cyclopropylmethoxy- oder Cyclopentyl
methoxygruppe und
Rc eine R3-(CH2)m-O-Gruppe, in der
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylaminogruppe
oder eine durch zwei Methylgruppen substituierte 2-Oxo-
morpholin-4-yl-Gruppe und
m die Zahl 2 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-7-[2-(6,6-dimethyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentyloxy-china
zolin und
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro
furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentylmethoxy-
chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.
Very particularly preferred compounds of general formula I are also those in which
R a is a 3-chloro-4-fluoro-phenyl group,
R b is a cyclopentyloxy, cyclopropylmethoxy or cyclopentyl methoxy group and
R c is an R 3 - (CH 2 ) m -O- group in which
R 3 is an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino group or a 2-oxomorpholin-4-yl group substituted by two methyl groups;
m represent the number 2,
with the proviso mean that the connections
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentyloxy-china zolin and
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentylmethoxyquinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Als ganz besonders bevorzugte Verbindungen seien beispielswei
se folgende erwähnt:
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentylmethoxy-
7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-N-methyl-amino]-ethoxy}-
chinazolin,
(3) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy-
7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
(4) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclobutyloxy-
6-[3-(2,2-dimethyl-6-oxo-morpholin-4-yl)-propyloxy]-china
zolin,
(5) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclopropylmethoxy-
6-[3-(2,2-dimethyl-6-oxo-morpholin-4-yl)-propyloxy]-china
zolin,
(7) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy-
7-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-N-methyl-amino]-ethoxy}-
chinazolin,
(8) 4-[(3-Brom-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpho
lin-4-yl)-ethoxy]-7-methoxy-chinazolin,
(9) 4-[(3-Brom-phenyl)amino]-6-[2-((R)-6-methyl-2-oxo-morpho
lin-4-yl)-ethoxy]-7-methoxy-chinazolin,
(10) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-((R)-6-methyl-
2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
(11) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-((R)-6-methyl-
2-oxo-morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin,
(12) 4-[(R)-(1-Phenyl-ethyl)amino]-6-[3-((S)-6-methyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin und
(13) 4-[(R)-(1-Phenyl-ethyl)amino]-6-[2-((S)-6-methyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
deren Tautomeren, deren Stereoisomere und deren Salze.As very particularly preferred compounds, the following may be mentioned, for example:
(1) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentylmethoxy-7- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] - quinazoline,
(2) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} - quinazoline,
(3) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopropylmethoxy-7- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] - quinazoline,
(4) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -7-cyclobutyloxy-6- [3- (2,2-dimethyl-6-oxo-morpholin-4-yl) -propyloxy] - china zolin,
(5) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -7-cyclopropylmethoxy-6- [3- (2,2-dimethyl-6-oxomorpholin-4-yl) -propyloxy] - china zolin,
(7) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopropylmethoxy-7- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} - quinazoline,
(8) 4 - [(3-Bromo-phenyl) -amino] -6- [2 - ((S) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline .
(9) 4 - [(3-Bromo-phenyl) -amino] -6- [2 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline .
(10) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7- -methoxy-quinazoline,
(11) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -propyloxy] -7- methoxy-quinazoline,
(12) 4 - [(R) - (1-phenylethyl) amino] -6- [3 - ((S) -6-methyl-2-oxomorpholin-4-yl) -propyloxy] -7- methoxy-quinazoline and
(13) 4 - [(R) - (1-phenylethyl) amino] -6- [2 - ((S) -6-methyl-2-oxomorpholin-4-yl) -ethoxy] -7- methoxy-quinazoline,
their tautomers, their stereoisomers and their salts.
Die Verbindungen der allgemeinen Formel I lassen sich
beispielsweise nach folgenden Verfahren herstellen:
The compounds of general formula I can be prepared, for example, by the following processes:
-
a) Umsetzung einer Verbindung der allgemeinen Formel
in der
Ra wie eingangs erwähnt definiert ist,
einer der Reste Rb' oder Rc' eine Methoxy-, Cyclobutyloxy-, Cyclopentyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclopentylmethoxygruppe darstellt und
der andere der Reste Rb' oder Rc' eine Z1-(CH2)m-O-Gruppe darstellt, in der
m wie eingangs erwähnt definiert ist und
Z1 eine Austrittsgruppe wie ein Halogenatom oder eine Sulfonyloxygruppe wie ein Chlor- oder Bromatom, eine Methansulfonyloxy- oder p-Toluolsulfonyloxygruppe bedeutet, mit einer Verbindung der allgemeinen Formel
H - R3, (III)
in der
R3 wie eingangs erwähnt definiert ist.a) reaction of a compound of the general formula
in the
R a is defined as mentioned above,
one of R b 'or R c ' represents a methoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group and
the other of R b 'or R c ' represents a Z 1 - (CH 2 ) m -O- group in which
m is defined as mentioned above and
Z 1 represents a leaving group such as a halogen atom or a sulphonyloxy group such as a chlorine or bromine atom, a methanesulphonyloxy or p-toluenesulphonyloxy group, with a compound of the general formula
H - R 3 , (III)
in the
R 3 is defined as mentioned above.
Die Umsetzung wird gegebenenfalls in einem Lösungsmittel oder Lösungsmittelgemisch wie Methylenchlorid, Acetonitril, Dime thylformamid, Dimethylsulfoxid, Sulfolan, Benzol, Toluol, Chlorbenzol, Tetrahydrofuran, Benzol/Tetrahydrofuran oder Dioxan zweckmäßigerweise in Gegenwart einer tertiären or ganischen Base wie Triethylamin oder N-Ethyl-diisopropylamin, wobei diese organischen Basen gleichzeitig auch als Lösungs mittel dienen können, oder in Gegenwart einer anorganischen Base wie Natriumkarbonat oder Kaliumcarbonat zweckmäßigerweise bei Temperaturen zwischen -20 und 200°C, vorzugsweise bei Temperaturen zwischen 0 und 150°C, durchgeführt.The reaction is optionally carried out in a solvent or Solvent mixture such as methylene chloride, acetonitrile, dime thylformamide, dimethyl sulfoxide, sulfolane, benzene, toluene, Chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or Dioxane expediently in the presence of a tertiary or ganic base such as triethylamine or N-ethyldiisopropylamine, these organic bases are also used as solutions can serve, or in the presence of an inorganic Base such as sodium carbonate or potassium carbonate expediently at temperatures between -20 and 200 ° C, preferably at Temperatures between 0 and 150 ° C, performed.
-
a) Cyclisierung einer gegebenenfalls im Reaktionsgemisch
gebildeten Verbindung der allgemeinen Formel
in der
Ra wie eingangs erwähnt definiert ist,
einer der Reste Rb'' oder Rc'' eine Methoxy-, Cyclobutyloxy-, Cyclopentyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclopentylmethoxygruppe darstellt und
der andere der Reste Rb'' oder Rc'' eine R3'-(CH2)m-O-Gruppe dar stellt, in der
m wie eingangs erwähnt definiert ist und
R3' eine an den Methylengruppen durch eine oder zwei Methyl- oder Ethylgruppen substituierte R4-O-CO-CH2-N-CH2CH2-OH-Gruppe bedeutet, in der
R4 ein Wasserstoffatom oder eine C1-4-Alkylgruppe darstellt.a) cyclization of an optionally formed in the reaction mixture of the general formula
in the
R a is defined as mentioned above,
one of R b "or R c " represents a methoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group and
the other of R b "or R c " represents an R 3 '- (CH 2 ) m -O- group in which
m is defined as mentioned above and
R 3 'represents a R 4 -O-CO-CH 2 -N-CH 2 CH 2 -OH group substituted on the methylene groups by one or two methyl or ethyl groups, in which
R 4 represents a hydrogen atom or a C 1-4 alkyl group.
Die Umsetzung wird gegebenenfalls in einem Lösungsmittel oder Lösungsmittelgemisch wie Methylenchlorid, Acetonitril, Dime thylformamid, Dimethylsulfoxid, Sulfolan, Benzol, Toluol, Chlorbenzol, Tetrahydrofuran, Benzol/Tetrahydrofuran oder Dioxan zweckmäßigerweise in Gegenwart einer wasserfreien Säure wie Trifluoressigsäure, Methansulfonsäure oder Schwefelsäure oder in Gegenwart eines wasserentziehenden Mittels, z. B. in Gegenwart von Chlorameisensäureisobutylester, Thionylchlorid, Trimethylchlorsilan, Phosphortrichlorid, Phosphorpentoxid, N,N'-Dicyclohexylcarbodiimid, N,N'-Dicyclohexylcarbodi imid/N-Hydroxysuccinimid oder 1-Hydroxy-benztriazol, N,N'-Carbonyldiimidazol oder Triphenylphosphin/Tetrachlorkoh leristoff, bei Temperaturen zwischen -20 und 200°C, vorzugswei se jedoch bei Temperaturen zwischen -10 und 160°C, durchge führt.The reaction is optionally carried out in a solvent or Solvent mixture such as methylene chloride, acetonitrile, dime thylformamide, dimethyl sulfoxide, sulfolane, benzene, toluene, Chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or Dioxane conveniently in the presence of an anhydrous acid such as trifluoroacetic acid, methanesulfonic acid or sulfuric acid or in the presence of a dehydrating agent, e.g. In The presence of isobutyl chloroformate, thionyl chloride, Trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N, N'-dicyclohexylcarbodiimide, N, N'-dicyclohexylcarbodi imide / N-hydroxysuccinimide or 1-hydroxybenzotriazole, N, N'-carbonyldiimidazole or triphenylphosphine / carbon tetrachloride Leristoff, at temperatures between -20 and 200 ° C, vorzugswei However, at temperatures between -10 and 160 ° C, Runaway leads.
Bei den vorstehend beschriebenen Umsetzungen können gegebenen falls vorhandene reaktive Gruppen wie Hydroxy-, Carboxy- oder Iminogruppen während der Umsetzung durch übliche Schutzgruppen geschützt werden, welche nach der Umsetzung wieder abgespalten werden.In the reactions described above can be given if existing reactive groups such as hydroxy, carboxy or Imino groups during the reaction by conventional protecting groups be protected, which split off again after the implementation become.
Beispielsweise kommt als Schutzrest für eine Hydroxygruppe die
Trimethylsilyl-, Acetyl-, Benzoyl-, Methyl-, Ethyl-, tert.Bu
tyl-, Trityl-, Benzyl- oder Tetrahydropyranylgruppe,
als Schutzreste für eine Carboxygruppe die Trimethylsilyl-,
Methyl-, Ethyl-, tert.Butyl-, Benzyl- oder Tetrahydropyran
ylgruppe und
als Schutzreste für eine Iminogruppe die Formyl-, Acetyl-,
Trifluoracetyl-, Ethoxycarbonyl-, tert.Butoxycarbonyl-,
Benzyloxycarbonyl-, Benzyl-, Methoxybenzyl- oder
2,4-Dimethoxybenzylgruppe in Betracht.For example, the protective radical for a hydroxy group is trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert.butyl, trityl, benzyl or tetrahydropyranyl,
as protecting groups for a carboxy group, the trimethylsilyl, methyl, ethyl, tert-butyl, benzyl or tetrahydropyran yl group and
as protecting groups for an imino group, the formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group into consideration.
Die gegebenenfalls anschließende Abspaltung eines verwendeten Schutzrestes erfolgt beispielsweise hydrolytisch in einem wässrigen Lösungsmittel, z. B. in Wasser, Isopropanol/Wasser, Essigsäure/Wasser, Tetrahydrofuran/Wasser oder Dioxan/Wasser, in Gegenwart einer Säure wie Trifluoressigsäure, Salzsäure oder Schwefelsäure oder in Gegenwart einer Alkalibase wie Natriumhydroxid oder Kaliumhydroxid oder aprotisch, z. B. in Gegenwart von Jodtrimethylsilan, bei Temperaturen zwischen 0 und 120°C, vorzugsweise bei Temperaturen zwischen 10 und 100°C.The optional subsequent cleavage of a used Protective remnant takes place for example hydrolytically in one aqueous solvent, for. In water, isopropanol / water, Acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali metal base such as Sodium hydroxide or potassium hydroxide or aprotic, z. In Presence of iodotrimethylsilane, at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.
Die Abspaltung eines Benzyl-, Methoxybenzyl- oder Benzyloxy carbonylrestes erfolgt jedoch beispielsweise hydrogenolytisch, z. B. mit Wasserstoff in Gegenwart eines Katalysators wie Pal ladium/Kohle in einem geeigneten Lösungsmittel wie Methanol, Ethanol, Essigsäureethylester oder Eisessig gegebenenfalls unter Zusatz einer Säure wie Salzsäure bei Temperaturen zwi schen 0 und 100°C, vorzugsweise jedoch bei Raumtemperaturen zwischen 20 und 60°C, und bei einem Wasserstoffdruck von 1 bis 7 bar, vorzugsweise jedoch von 3 bis 5 bar. Die Abspaltung eines 2,4-Dimethoxybenzylrestes erfolgt jedoch vorzugsweise in Trifluoressigsäure in Gegenwart von Anisol.The cleavage of a benzyl, methoxybenzyl or benzyloxy However, carbonyl radical is hydrogenolytically, for example, z. B. with hydrogen in the presence of a catalyst such as Pal ladium / coal in a suitable solvent such as methanol, Ethanol, ethyl acetate or glacial acetic acid, if appropriate with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 ° C, but preferably at room temperatures between 20 and 60 ° C, and at a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar. The spin-off However, a 2,4-dimethoxybenzyl radical is preferably carried out in Trifluoroacetic acid in the presence of anisole.
Die Abspaltung eines tert.Butyl- oder tert.Butyloxycarbonyl restes erfolgt vorzugsweise durch Behandlung mit einer Säure wie Trifluoressigsäure oder Salzsäure oder durch Behandlung mit Jodtrimethylsilan gegebenenfalls unter Verwendung eines Lösungsmittels wie Methylenchlorid, Dioxan, Methanol oder Diethylether.The cleavage of a tert-butyl or tert-butyloxycarbonyl The rest is preferably carried out by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with iodotrimethylsilane optionally using a Solvent such as methylene chloride, dioxane, methanol or Diethyl ether.
Die Abspaltung eines Trifluoracetylrestes erfolgt vorzugsweise durch Behandlung mit einer Säure wie Salzsäure gegebenenfalls in Gegenwart eines Lösungsmittels wie Essigsäure bei Tempera turen zwischen 50 und 120°C oder durch Behandlung mit Natron lauge gegebenenfalls in Gegenwart eines Lösungsmittels wie Te trahydrofuran bei Temperaturen zwischen 0 und 50°C.The cleavage of a Trifluoracetylrestes is preferably carried out by treatment with an acid such as hydrochloric acid if necessary in the presence of a solvent such as acetic acid at tempera between 50 and 120 ° C or by treatment with soda optionally in the presence of a solvent such as Te trahydrofuran at temperatures between 0 and 50 ° C.
Ferner können die erhaltenen Verbindungen der allgemeinen For mel I, wie bereits eingangs erwähnt wurde, in ihre Enantiome ren und/oder Diastereomeren aufgetrennt werden. So können bei spielsweise cis-/trans-Gemische in ihre cis- und trans-Iso mere, und Verbindungen mit mindestens einem optisch aktiven Kohlenstoffatom in ihre Enantiomeren aufgetrennt werden.Further, the obtained compounds of the general For mel I, as already mentioned, into their enantiomers ren and / or diastereomers are separated. So can at For example, cis / trans mixtures into their cis and trans iso mers, and compounds having at least one optically active Carbon atom are separated into their enantiomers.
So lassen sich beispielsweise die erhaltenen cis-/trans-Ge mische durch Chromatographie in ihre cis- und trans-Isomeren, die erhaltenen Verbindungen der allgemeinen Formel I, welche in Racematen auftreten, nach an sich bekannten Methoden (siehe Allinger N.L. und Eliel E.L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971)) in ihre optischen Antipoden und Verbindungen der allgemeinen Formel I mit mindestens 2 asymmetrischen Kohlenstoffatomen auf Grund ihrer physikalisch chemischen Unterschiede nach an sich bekannten Methoden, z. B. durch Chromatographie und/oder fraktionierte Kristallisation, in ihre Diastereomeren auftrennen, die, falls sie in racemi scher Form anfallen, anschließend wie oben erwähnt in die Enantiomeren getrennt werden können.For example, the resulting cis- / trans-Ge mix by chromatography in their cis and trans isomers, the resulting compounds of general formula I, which occur in racemates, according to methods known per se (see Allinger N.L. and Eliel E.L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971)) into their optical antipodes and compounds of the general formula I with at least 2 asymmetric carbon atoms due to their physical chemical differences according to known methods, eg. B. by chromatography and / or fractional crystallisation, into their diastereomers, which, if they are in racemi shear form, then as mentioned above in the Enantiomers can be separated.
Die Enantiomerentrennung erfolgt vorzugsweise durch Säulen trennung an chiralen Phasen oder durch Umkristallisieren aus einem optisch aktiven Lösungsmittel oder durch Umetzen mit einer, mit der racemischen Verbindung Salze oder Derivate wie z. B. Ester oder Amide bildenden optisch aktiven Substanz, ins besondere Säuren und ihre aktivierten Derivate oder Alkohole, und Trennen des auf diese Weise erhaltenen diastereomeren Salzgemisches oder Derivates, z. B. auf Grund von verschiedenen Löslichkeiten, wobei aus den reinen diastereomeren Salzen oder Derivaten die freien Antipoden durch Einwirkung geeigneter Mittel freigesetzt werden können. Besonders gebräuchliche, optisch aktive Säuren sind z. B. die D- und L-Formen von Wein säure oder Dibenzoylweinsäure, Di-o-Tolylweinsäure, Äpfelsäu re, Mandelsäure, Camphersulfonsäure, Glutaminsäure, Asparagin säure oder Chinasäure. Als optisch aktiver Alkohol kommt bei spielsweise (+)- oder (-)-Menthol und als optisch aktiver Acylrest in Amiden beispielsweise (+)- oder (-)-Menthyloxycar bonyl in Betracht.The enantiomer separation is preferably carried out by columns separation on chiral phases or by recrystallization an optically active solvent or by reacting with one, with the racemic compound salts or derivatives like z. As esters or amides-forming optically active substance, ins particular acids and their activated derivatives or alcohols, and separating the diastereomers thus obtained Salt mixture or derivative, e.g. B. due to different Solubilities, wherein from the pure diastereomeric salts or Derivatives the free antipodes by action appropriate Funds can be released. Especially common, optically active acids are, for. B. the D and L forms of wine acid or dibenzoyltartaric acid, di-o-toluenoic acid, malic acid almic acid, camphorsulfonic acid, glutamic acid, asparagine acid or quinic acid. As optically active alcohol comes for example, (+) - or (-) - menthol and as optically active Acyl radical in amides, for example, (+) - or (-) - Menthyloxycar consider bonyl.
Desweiteren können die erhaltenen Verbindungen der Formel I in ihre Salze, insbesondere für die pharmazeutische Anwendung in ihre physiologisch verträglichen Salze mit anorganischen oder organischen Säuren, übergeführt werden. Als Säuren kommen hierfür beispielsweise Salzsäure, Bromwasserstoffsäure, Schwe felsäure, Methansulfonsäure, Phosphorsäure, Fumarsäure, Bern steinsäure, Milchsäure, Zitronensäure, Weinsäure oder Malein säure in Betracht.Furthermore, the compounds of the formula I can be obtained in their salts, in particular for pharmaceutical use in their physiologically acceptable salts with inorganic or organic acids are transferred. When acids come for example, hydrochloric acid, hydrobromic acid, sw felsic acid, methanesulfonic acid, phosphoric acid, fumaric acid, Bern tartaric acid, lactic acid, citric acid, tartaric acid or malein acid into consideration.
Außerdem lassen sich die so erhaltenen neuen Verbindungen der Formel I, falls diese eine Carboxy-, Hydroxyphosphoryl-, Sulfo- oder 5-Tetrazolylgruppe enthalten, gewünschtenfalls anschließend in ihre Salze mit anorganischen oder organischen Basen, insbesondere für die pharmazeutische Anwendung in ihre physiologisch verträglichen Salze, überführen. Als Basen kommen hierbei beispielsweise Natriumhydroxid, Kaliumhydroxid, Arginin, Cyclohexylamin, Ethanolamin, Diethanolamin und Triethanolamin in Betracht.In addition, the new compounds thus obtained can be Formula I, if these are a carboxy, hydroxyphosphoryl, Contain sulfo or 5-tetrazolyl, if desired then in their salts with inorganic or organic Bases, especially for the pharmaceutical application in their physiologically acceptable salts. As bases For example, sodium hydroxide, potassium hydroxide, Arginine, cyclohexylamine, ethanolamine, diethanolamine and Triethanolamine into consideration.
Die als Ausgangsstoffe verwendeten Verbindungen der allgemei nen Formeln II bis IV sind teilweise literaturbekannt oder man erhält diese nach an sich literaturbekannten Verfahren (siehe Beispiele I bis XIV).The compounds used as starting materials of the general NEN Formulas II to IV are partially known from the literature or man receives these according to the literature known methods (see Examples I to XIV).
Wie bereits eingangs erwähnt, weisen die erfindungsgemäßen Verbindungen der allgemeinen Formel I und ihre physiologisch verträglichen Salze wertvolle pharmakologische Eigenschaften auf, insbesondere eine Hemmwirkung auf die durch den Epidermal Growth Factor-Rezeptor (EGF-R) vermittelte Signaltransduktion, wobei diese beispielsweise durch eine Inhibition der Liganden bindung, der Rezeptordimerisierung oder der Tyrosinkinase selbst bewirkt werden kann. Außerdem ist es möglich, daß die Signalübertragung an weiter abwärtsliegenden Komponenten blockiert wird.As already mentioned, the inventive Compounds of general formula I and their physiological Compatible salts have valuable pharmacological properties on, in particular, an inhibitory effect on that through the epidermis Growth Factor Receptor (EGF-R) mediated signal transduction, this being due, for example, to inhibition of the ligands binding, receptor dimerization or tyrosine kinase itself can be effected. It is also possible that the Signal transmission to further downstream components is blocked.
Die biologischen Eigenschaften der neuen Verbindungen wurden
wie folgt geprüft:
Die Hemmung der EGF-R vermittelten Signalübertragung kann z. B.
mit Zellen nachgewiesen werden, die humanen EGF-R exprimieren
und deren Überleben und Proliferation von Stimulierung durch
EGF bzw. TGF-alpha abhängt. Hier wurde eine Interleukin-
3-(IL-3) abhängige Zellinie murinen Ursprungs verwendet, die
derart genetisch verändert wurde, daß sie funktionellen hu
manen EGF-R exprimiert. Die Proliferation dieser F/L-HERc
genannten Zellen kann daher entweder durch murines IL-3 oder
durch EGF stimuliert werden (siehe von Rüden, T. et al. in
EMBO J. 7, 2749-2756 (1988) und Pierce, J.H. et al. in
Science 239, 628-631 (1988)).The biological properties of the new compounds were tested as follows:
The inhibition of EGF-R-mediated signal transmission can e.g. B. can be detected with cells that express human EGF-R and their survival and proliferation depends on stimulation by EGF or TGF-alpha. Here, an interleukin 3- (IL-3) -dependent cell line of murine origin was used, which was genetically engineered to express functional human EGF-R. The proliferation of these cells called F / L-HERc can therefore be stimulated either by murine IL-3 or by EGF (see by Rüden, T. et al., EMBO J. 7, 2749-2756 (1988) and Pierce, JH et in Science 239, 628-631 (1988)).
Als Ausgangsmaterial für die F/L-HERc Zellen diente die Zell linie FDC-P1, deren Herstellung von Dexter, T.M. et al. in J. Exp. Med. 152, 1036-1047 (1980) beschrieben wurde. Alternativ können aber auch andere Wachstumsfaktor-abhängige Zellen ver wendet werden (siehe beispielsweise Pierce, J.H. et al. in Science 239, 628-631 (1988), Shibuya, H. et al. in Cell 70, 57-67 (1992) und Alexander, W.S. et al. in EMBO J. 10, 3683-3691 (1991)). Zur Expression der humanen EGF-R cDNA (siehe Ullrich, A. et al. in Nature 309, 418-425 (1984)) wurden re kombinante Retroviren verwendet, wie in von Rüden, T. et al., EMBO J. 7, 2749-2756 (1988) beschrieben, mit dem Unterschied, daß zur Expression der EGF-R cDNA der retrovirale Vektor LXSN (siehe Miller, A.D. et al. in BioTechniques 7, 980-990 (1989)) eingesetzt wurde und als Verpackungszelle die Linie GP+E86 (siehe Markowitz, D. et al. in J. Virol. 62, 1120-1124 (1988)) diente.The starting material for the F / L-HERc cells was the cell line FDC-P 1 , the preparation of which was obtained from Dexter, TM et al. in J. Exp. Med. 152, 1036-1047 (1980). Alternatively, however, other growth factor-dependent cells may be used (see, for example, Pierce, JH et al., Science 239, 628-631 (1988), Shibuya, H. et al., Cell 70, 57-67 (1992) and Alexander, WS et al., EMBO J. 10, 3683-3691 (1991)). For expression of the human EGF-R cDNA (see Ullrich, A. et al., Nature 309, 418-425 (1984)), recombinant retroviruses were used as described in Rüden, T. et al., EMBO J. 7, 2749-2756 (1988), except that the retroviral vector LXSN (see Miller, AD et al., BioTechniques 7, 980-990 (1989)) was used to express the EGF-R cDNA and the line as the packaging cell GP + E86 (see Markowitz, D. et al., J. Virol., 62, 1120-1124 (1988)).
Der Test wurde wie folgt durchgeführt:
F/L-HERc Zellen wurden in RPMI/1640 Medium (BioWhittaker),
supplementiert mit 10% foetalem Rinderserum (FCS, Boehringer
Mannheim), 2 mM Glutamin (BioWhittaker), Standardantibiotika
und 20 ng/ml humanem EGF (Promega), bei 37°C und 5% CO2 kulti
viert. Zur Untersuchung der inhibitorischen Aktivität der er
findungsgemäßen Verbindungen wurden 1,5 × 104 Zellen pro Ver
tiefung in Triplikaten in 96-Loch-Platten in obigem Medium
(200 µl) kultiviert, wobei die Proliferation der Zellen ent
weder mit EGF (20 ng/ml) oder murinem IL-3 stimuliert wurde.
Als Quelle für IL-3 dienten Kulturüberstände der Zellinie
X63/0 mIL-3 (siehe Karasuyama, H. et al. in Eur. J. Immunol.
18, 97-104 (1988)). Die erfindungsgemäßen Verbindungen wurden
in 100% Dimethylsulfoxid (DMSO) gelöst und in verschiedenen
Verdünnungen den Kulturen zugefügt, wobei die maximale DMSO
Konzentration 1% betrug. Die Kulturen wurden für 48 Stunden
bei 37°C inkubiert.The test was carried out as follows:
F / L-HERc cells were transfected into RPMI / 1640 medium (BioWhittaker) supplemented with 10% fetal bovine serum (FCS, Boehringer Mannheim), 2 mM glutamine (BioWhittaker), standard antibiotics and 20 ng / ml human EGF (Promega) at 37 ° C and 5% CO 2 cultivated. To investigate the inhibitory activity of the compounds according to the invention, 1.5 × 10 4 cells per well were cultivated in triplicates in 96-well plates in the above medium (200 μl), the proliferation of the cells either with EGF (20 ng / ml) or murine IL-3. Culture supernatants of the cell line X63 / mIL-3 served as a source of IL-3 (see Karasuyama, H. et al., Eur. J. Immunol., 18, 97-104 (1988)). The compounds according to the invention were dissolved in 100% dimethyl sulfoxide (DMSO) and added to the cultures in various dilutions, the maximum DMSO concentration being 1%. The cultures were incubated for 48 hours at 37 ° C.
Zur Bestimmung der inhibitorischen Aktivität der erfindungs
gemäßen Verbindungen wurde die relative Zellzahl mit dem Cell
Titer 96™ AQueous Non-Radioactive Cell Proliferation Assay
(Promega) in O.D. Einheiten gemessen. Die relative Zellzahl
wurde in Prozent der Kontrolle (F/LHERc Zellen ohne Inhibitor)
berechnet und die Wirkstoffkonzentration, die die Prolifera
tion der Zellen zu 50% hemmt (IC50), abgeleitet. Hierbei wur
den folgende Ergebnisse erhalten:
To determine the inhibitory activity of the compounds according to the invention the relative cell number of the Cell Titer 96 ™ AQ ueous Non-Radioactive Cell Proliferation Assay (Promega) was measured in OD units. The relative cell count was calculated as a percentage of the control (F / LHERc cells without inhibitor) and the drug concentration, which inhibits the proliferation of the cells to 50% (IC 50 ) derived. The following results were obtained:
Die erfindungsgemäßen Verbindungen der allgemeinen Formel I hemmen somit die Signaltransduktion durch Tyrosinkinasen, wie am Beispiel des humanen EGF-Rezeptors gezeigt wurde, und sind daher nützlich zur Behandlung pathophysiologischer Prozesse, die durch Überfunktion von Tyrosinkinasen hervorgerufen werden. Das sind z. B. benigne oder maligne Tumoren, insbesondere Tumoren epithelialen und neuroepithelialen Ursprungs, Metastasierung sowie die abnorme Proliferation vaskulärer Endothelzellen (Neoangiogenese).The compounds of general formula I according to the invention thus inhibit signal transduction by tyrosine kinases, such as has been shown by the example of the human EGF receptor, and are therefore useful for the treatment of pathophysiological processes, caused by hyperfunction of tyrosine kinases become. These are z. Benign or malignant tumors, especially tumors epithelial and neuroepithelial Origin, metastasis and abnormal proliferation vascular endothelial cells (neoangiogenesis).
Die erfindungsgemäßen Verbindungen sind auch nützlich zur Vorbeugung und Behandlung von Erkrankungen der Atemwege und der Lunge, die mit einer vermehrten oder veränderten Schleimproduktion einhergehen, die durch Stimulation von Tyrosinkinasen hervorgerufen wird, wie z. B. bei entzündlichen Erkrankungen der Atemwege wie chronische Bronchitis, chronisch obstruktive Bronchitis, Asthma, Bronchiektasien, allergische oder nicht-allergische Rhinitis oder Sinusitis, zystische Fibrose, α1-Antitrypsin-Mangel, oder bei Husten, Lungen emphysem, Lungenfibrose und hyperreaktiven Atemwegen.The compounds of the invention are also useful for Prevention and treatment of respiratory diseases and the lungs that multiplied or changed Mucus production is accompanied by stimulation of Tyrosine kinases is caused, such. B. in inflammatory Respiratory diseases such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic Fibrosis, α1-antitrypsin deficiency, or in cough, lungs emphysema, pulmonary fibrosis and hyperreactive airways.
Die Verbindungen sind auch geeignet für die Behandlung von Er
krankungen des Magen-Darm-Traktes und der Gallengänge und
-blase, die mit einer gestörten Aktivität der Tyrosinkinasen
einhergehen, wie sie z. B. bei chronisch entzündlichen
Veränderungen zu finden sind, wie Cholezystitis, M. Crohn,
Colitis ulcerosa, und Geschwüren im Magen-Darm-Trakt oder wie
sie bei Erkrankungen des Magen-Darm-Traktes, die mit einer
vermehrten Sekretion einhergehen, vorkommen, wie M. Menetrier,
sezernierende Adenome und Proteinverlustsyndrome,
desweiteren zur Behandlung von Nasenpolypen sowie von Polypen
des Gastrointestinaltraktes unterschiedlicher Genese wie z. B.
villöse oder adenomatöse Polypen des Dickdarms, aber auch von
Polypen bei familiärer Polyposis coli, bei Darmpolypen im Rah
men des Gardner-Syndroms, bei Polypen im gesamten Magen-Darm-
Trakt bei Peutz-Jeghers-Syndrom, bei entzündlichen
Pseudopolypen, bei juvenilen Polypen, bei Colitis cystica
profunda und bei Pneumatosis cystoides intestinales.The compounds are also suitable for the treatment of disorders of the gastrointestinal tract and the bile ducts and bladder, which are associated with a disrupted activity of tyrosine kinases, as z. B. in chronic inflammatory changes, such as cholecystitis, Crohn's disease, ulcerative colitis, and ulcers in the gastrointestinal tract or as they occur in diseases of the gastrointestinal tract, which are associated with increased secretion, such as M. Menetrier, secreting adenomas and protein loss syndromes,
Furthermore, for the treatment of nasal polyps and polyps of the gastrointestinal tract of different genesis such. As villous or adenomatous polyps of the colon, but also of polyps in familial polyposis coli, intestinal polyps in the context of Gardner syndrome, in polyps throughout the gastrointestinal tract in Peutz-Jeghers syndrome, in inflammatory pseudopolyps, in juvenile Polyps, in colitis cystica profunda and in pneumatosis cystoides intestinales.
Außerdem können die Verbindungen der allgemeinen Formel I und deren physiologisch verträglichen Salze zur Behandlung von Nierenerkrankungen, insbesondere bei zystischen Veränderungen wie bei Zystennieren, zur Behandlung von Nierenzysten, die idiopathischer Genese sein können oder im Rahmen von Syndromen auftreten wie z. B. bei der tuberöser Sklerose, bei dem von- Hippel-Lindau-Syndrom, bei der Nephronophthisis und Markschwammniere sowie anderer Krankheiten verwendet werden, die durch aberrante Funktion von Tyrosinkinasen verursacht werden, wie z. B. epidermaler Hyperproliferation (Psoriasis), inflammatorischer Prozesse, Erkrankungen des Immunsystems, Hyperproliferation hämatopoetischer Zellen etc.In addition, the compounds of general formula I and their physiologically acceptable salts for the treatment of Kidney disease, especially in cystic changes as in cystic kidney, for the treatment of renal cysts, the idiopathic genesis or in the context of syndromes occur such. In tuberous sclerosis, in the case of Hippel-Lindau syndrome, in nephronophthisis and Medullary sponge kidney as well as other diseases are used, which causes by aberrant function of tyrosine kinases be such. B. epidermal hyperproliferation (psoriasis), inflammatory processes, diseases of the immune system, Hyperproliferation of hematopoietic cells, etc.
Auf Grund ihrer biologischen Eigenschaften können die erfindungsgemäßen Verbindungen allein oder in Kombination mit anderen pharmakologisch wirksamen Verbindungen angewendet werden, beispielsweise in der Tumortherapie in Monotherapie oder in Kombination mit anderen Anti-Tumor Therapeutika, beispielsweise in Kombination mit Topoisomerase-Inhibitoren (z. B. Etoposide), Mitoseinhibitoren (z. B. Vinblastin), mit Nukleinsäuren interagierenden Verbindungen (z. B. cis-Platin, Cyclophosphamid, Adriamycin), Hormon-Antagonisten (z. B. Tamoxifen), Inhibitoren metabolischer Prozesse (z. B. 5-FU etc.), Zytokinen (z. B. Interferonen), Antikörpern etc. Für die Behandlung von Atemwegserkrankungen können diese Verbindungen allein oder in Kombination mit anderen Atemwegstherapeutika, wie z. B. sekretolytisch, broncholytisch und/oder entzündungshemmend wirksamen Substanzen angewendet werden. Für die Behandlung von Erkrankungen im Bereich des Magen-Darm- Traktes können diese Verbindungen ebenfalls alleine oder in Kombination mit Motilitäts- oder Sekretions-beeinflussenden oder entzündungshemmenden Substanzen gegeben werden. Diese Kombinationen können entweder simultan oder sequentiell ver abreicht werden.Due to their biological properties, the Compounds of the invention alone or in combination with applied to other pharmacologically active compounds be, for example in tumor therapy in monotherapy or in combination with other anti-tumor therapeutics, for example in combination with topoisomerase inhibitors (eg, etoposide), mitotic inhibitors (eg, vinblastine), with Nucleic acid interacting compounds (eg, cis-platin, Cyclophosphamide, adriamycin), hormone antagonists (eg. Tamoxifen), inhibitors of metabolic processes (eg 5-FU etc.), cytokines (eg interferons), antibodies etc. For the Respiratory treatments can use these compounds alone or in combination with other respiratory therapies, such as B. secretolytic, broncholytic and / or anti-inflammatory substances are used. For the treatment of diseases in the area of the gastrointestinal tract Traktes may also be used alone or in these compounds Combination with motility or secretion-influencing or anti-inflammatory substances. These Combinations can be performed either simultaneously or sequentially be submitted.
Die Anwendung dieser Verbindungen entweder alleine oder in Kombination mit anderen Wirkstoffen kann intravenös, subkutan, intramuskulär, intrarektal, intraperitoneal, intranasal, durch Inhalation oder transdermal oder oral erfolgen, wobei zur Inhalation insbesondere Aerosolformulierungen geeignet sind.The application of these compounds either alone or in Combination with other active substances may be intravenous, subcutaneous, intramuscular, intrarectal, intraperitoneal, intranasal, through Inhalation or transdermally or orally, wherein the Inhalation in particular aerosol formulations are suitable.
Bei der pharmazeutischen Anwendung werden die erfindungsgemäßen Verbindungen in der Regel bei warmblütigen Wirbeltieren, insbesondere beim Menschen, in Dosierungen von 0,01-100 mg/kg Körpergewicht, vorzugsweise bei 0,1-15 mg/kg verwendet. Zur Verabreichung werden diese mit einem oder mehreren üblichen inerten Trägerstoffen und/oder Verdünnungsmitteln, z. B. mit Maisstärke, Milchzucker, Rohrzucker, mikrokristalliner Zellulose, Magnesiumstearat, Polyvinylpyrrolidon, Zitronensäure, Weinsäure, Wasser, Wasser/Ethanol, Wasser/Glycerin, Wasser/Sorbit, Wasser/Polyethylenglykol, Propylenglykol, Stearylalkohol, Carboxymethylcellulose oder fetthaltigen Substanzen wie Hartfett oder deren geeigneten Gemischen in übliche galenische Zubereitungen wie Tabletten, Dragées, Kapseln, Pulver, Suspen sionen, Lösungen, Sprays oder Zäpfchen eingearbeitet. In the pharmaceutical application, the Compounds according to the invention usually in warm-blooded Vertebrates, especially in humans, in dosages of 0.01-100 mg / kg body weight, preferably at 0.1-15 mg / kg used. For administration, these are with one or several customary inert carriers and / or Diluents, z. With cornstarch, lactose, Cane sugar, microcrystalline cellulose, magnesium stearate, Polyvinylpyrrolidone, citric acid, tartaric acid, water, Water / ethanol, water / glycerin, water / sorbitol, Water / polyethylene glycol, propylene glycol, stearyl alcohol, Carboxymethylcellulose or fatty substances such as Hard fat or their suitable mixtures in usual galenic Preparations such as tablets, dragees, capsules, powder, suspension ions, solutions, sprays or suppositories.
Die nachfolgenden Beispiele sollen die vorliegende Erfindung näher erläutern ohne diese zu beschränken: The following examples are intended to illustrate the present invention explain in more detail without limiting it:
Zu 3.50 g 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyl
methoxy-7-hydroxy-chinazolin und 6.89 ml 1,2-Dibromethan in
40 ml N,N-Dimethylformamid werden 4.84 g Kaliumcarbonat gege
ben. Das Reaktionsgemisch wird unter Stickstoff-Atmosphäre
1.5 Stunden bei 80°C gerührt. Nach Abkühlung auf Raumtempe
ratur wird das Reaktionsgemisch filtriert und das Filtrat im
Vakuum eingeengt. Der ölige, braune Rückstand wird im Eisbad
abgekühlt und mit wenig Methanol verrieben, wobei ein gelb
licher Feststoff auskristallisiert. Der Niederschlag wird ab
gesaugt, mit kaltem Methanol nachgewaschen und im Vakuumexsik
kator getrocknet.
Ausbeute: 2.60 g (58% der Theorie),
Rf-Wert: 0.82 (Kieselgel, Methylenchlorid/Methanol 9 : 1)
Massenspektrum (ESI+): m/z = 494, 496, 498 [M+H]+ To 3.50 g of 4 - [(3-chloro-4-fluorophenyl) amino] -6-cyclopentylmethoxy-7-hydroxyquinazoline and 6.89 ml of 1,2-dibromoethane in 40 ml of N, N-dimethylformamide are added 4.84 g of potassium carbonate give it. The reaction mixture is stirred under nitrogen atmosphere at 80 ° C for 1.5 hours. After cooling to room tempera ture, the reaction mixture is filtered and the filtrate concentrated in vacuo. The oily, brown residue is cooled in an ice bath and triturated with a little methanol, wherein a yellow Licher solid crystallized out. The precipitate is filtered off with suction, washed with cold methanol and dried in a vacuum desiccator.
Yield: 2.60 g (58% of theory),
R f value: 0.82 (silica gel, methylene chloride / methanol 9: 1)
Mass Spectrum (ESI + ): m / z = 494, 496, 498 [M + H] +
Analog Beispiel I werden folgende Verbindungen erhalten:
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy-
7-(2-brom-ethoxy)-chinazolin (Die Reaktion wird in Acetonitril
als Lösungsmittel durchgeführt)
Rf-Wert: 0.72 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI-): m/z = 464, 466, 468 [M-H]-
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-(2-brom-ethoxy)-chinazolin
Rf-Wert: 0.65 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI-): m/z = 478, 480, 482 [M-H]-
(3) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclobutyloxy-
6-(3-brom-propyloxy)-chinazolin (Die Reaktion wird in Aceto
nitril als Lösungsmittel durchgeführt)
Rf-Wert: 0.62 (Kieselgel, Methylenchlorid/Methanol 9 : 1)
Massenspektrum (ESI-): m/z = 478, 480, 482 [M-H]-
(4) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclopropylmethoxy-
6-(3-brom-propyloxy)-chinazolin (Die Reaktion wird in Aceto
nitril als Lösungsmittel durchgeführt)
Rf-Wert: 0.74 (Kieselgel, Methylenchlorid/Methanol 9 : 1)
Massenspektrum (ESI-): m/z = 478, 480, 482 [M-H]-
(5) 4-[(3-Brom-phenyl)amino]-6-(2-brom-ethoxy)-7-methoxy-
chinazolin
Schmelzpunkt: 244°C
Massenspektrum (ESI+): m/z = 452, 454, 456 [M+H]+
(6) 4-[(R)-(1-Phenyl-ethyl)amino]-6-(3-brom-propyloxy)-
7-methoxy-chinazolin (Die Reaktion wird mit Kalium-tert.bu
tylat als Base durchgeführt)
Rf-Wert: 0.60 (Kieselgel, Essigester/Methanol 9 : 1)
(7) 4-[(R)-(1-Phenyl-ethyl)amino]-6-(2-brom-ethoxy)-7-methoxy-
chinazolin (Die Reaktion wird mit Kalium-tert.butylat als Base
durchgeführt)
Schmelzpunkt: 255°C
Massenspektrum (ESI+): m/z = 402, 404 [M+H]+ Analogously to Example I, the following compounds are obtained:
(1) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopropylmethoxy-7- (2-bromo-ethoxy) -quinazoline (The reaction is carried out in acetonitrile as a solvent)
R f value: 0.72 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI -): m / z = 464, 466, 468 [MH] -
(2) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- (2-bromo-ethoxy) -quinazoline
R f value: 0.65 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI - ): m / z = 478, 480, 482 [MH] -
(3) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -7-cyclobutyloxy-6- (3-bromo-propyloxy) -quinazoline (The reaction is carried out in aceto-nitrile as a solvent)
R f value: 0.62 (silica gel, methylene chloride / methanol 9: 1)
Mass spectrum (ESI - ): m / z = 478, 480, 482 [MH] -
(4) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -7-cyclopropylmethoxy-6- (3-bromo-propyloxy) -quinazoline (The reaction is carried out in aceto-nitrile as a solvent)
R f value: 0.74 (silica gel, methylene chloride / methanol 9: 1)
Mass spectrum (ESI - ): m / z = 478, 480, 482 [MH] -
(5) 4 - [(3-Bromo-phenyl) -amino] -6- (2-bromo-ethoxy) -7-methoxy-quinazoline
Melting point: 244 ° C
Mass Spectrum (ESI + ): m / z = 452, 454, 456 [M + H] +
(6) 4 - [(R) - (1-Phenyl-ethyl) amino] -6- (3-bromo-propyloxy) -7-methoxy-quinazoline (The reaction is carried out with potassium tert-butylate as the base)
R f value: 0.60 (silica gel, ethyl acetate / methanol 9: 1)
(7) 4 - [(R) - (1-phenyl-ethyl) amino] -6- (2-bromo-ethoxy) -7-methoxy-quinazoline (The reaction is carried out with potassium tert -butylate as the base)
Melting point: 255 ° C
Mass spectrum (ESI + ): m / z = 402, 404 [M + H] +
4.99 g 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentylmethoxy-
7-methylcarbonyloxy-chinazolin werden in 80 ml Methanol sus
pendiert und mit 1.80 ml konzentrierter, wäßriger Ammoniak
lösung versetzt. Das Reaktionsgemisch wird über Nacht bei
Raumtemperatur gerührt. Zur Aufarbeitung wird das Reaktions
gemisch mit 500 ml Methylenchlorid verdünnt, mit Wasser und
gesättigter Natriumchlorid-Lösung gewaschen, über Magnesium
sulfat getrocknet und eingeengt. Man erhält 4.30 g eines
bräunlichen Feststoffes. Das Rohprodukt wird mit tert.Butyl
methylether verrührt, abgesaugt, mit wenig tert.Butylmethyl
ether nachgewaschen und bei Raumtemperatur im Vakuum getrock
net.
Ausbeute: 3.59 g (80% der Theorie),
Rf-Wert: 0.48 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 388, 340 [M+H]+ 4.99 g of 4 - [(3-chloro-4-fluorophenyl) amino] -6-cyclopentylmethoxy-7-methylcarbonyloxy-quinazoline are suspended in 80 ml of methanol and treated with 1.80 ml of concentrated, aqueous ammonia solution. The reaction mixture is stirred overnight at room temperature. For workup, the reaction mixture is diluted with 500 ml of methylene chloride, washed with water and saturated sodium chloride solution, dried over magnesium sulfate and concentrated. 4.30 g of a brownish solid are obtained. The crude product is stirred with tert.butyl methyl ether, filtered off with suction, washed with a little tert-butyl methyl ether and dried at room temperature in a vacuum.
Yield: 3.59 g (80% of theory),
R f value: 0.48 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass Spectrum (ESI + ): m / z = 388, 340 [M + H] +
Analog Beispiel II werden folgende Verbindungen erhalten:
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy-
7-hydroxy-chinazolin
Rf-Wert: 0.56 (Kieselgel, Methylenchlorid/Methanol 9 : 1)
Massenspektrum (ESI-): m/z = 358, 360 [M-H]-
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-hydroxy-chinazolin
Rf-Wert: 0.53 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 374, 376 [M+H]+
(3) 6-Benzyloxy-4-[(3-chlor-4-fluor-phenyl)amino]-7-hydroxy-
chinazolin
Rf-Wert: 0.54 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 396, 398 [M+H]+
(4) 4-[(3-Brom-phenyl)amino]-6-hydroxy-7-methoxy-chinazolin
(Die Reaktion wird mit Natronlauge in Ethanol als Lösungs
mittel durchgeführt)
Rf-Wert: 0.23 (Kieselgel, Essigester)
Massenspektrum (ESI+): m/z = 346, 348 [M+H]+ The following compounds are obtained analogously to Example II:
(1) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopropylmethoxy-7-hydroxy-quinazoline
R f value: 0.56 (silica gel, methylene chloride / methanol 9: 1)
Mass spectrum (ESI - ): m / z = 358, 360 [MH] -
(2) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7-hydroxy-quinazoline
R f value: 0.53 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI + ): m / z = 374, 376 [M + H] +
(3) 6-Benzyloxy-4 - [(3-chloro-4-fluoro-phenyl) -amino] -7-hydroxy-quinazoline
R f value: 0.54 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI + ): m / z = 396, 398 [M + H] +
(4) 4 - [(3-Bromo-phenyl) -amino] -6-hydroxy-7-methoxy-quinazoline (The reaction is carried out with sodium hydroxide in ethanol as a solvent)
R f value: 0.23 (silica gel, ethyl acetate)
Mass spectrum (ESI + ): m / z = 346, 348 [M + H] +
4.03 g 4-Chlor-6-cyclopentylmethoxy-7-methylcarbonyloxy-china
zolin werden in 70 ml Isopropanol suspendiert und mit 1.95 g
3-Chlor-4-fluor-anilin versetzt. Das Reaktionsgemisch wird
zwei Stunden unter Stickstoff-Atmosphäre refluxiert. Nach Ab
kühlung auf Raumtemperatur wird der entstandene helle Nieder
schlag abgesaugt, mit wenig Isopropanol nachgewaschen und an
der Luft getrocknet.
Ausbeute: 4.99 g (92% der Theorie),
Rf-Wert: 0.80 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 430, 432 [M+H]+ 4.03 g of 4-chloro-6-cyclopentylmethoxy-7-methylcarbonyloxy-china zoline are suspended in 70 ml of isopropanol and treated with 1.95 g of 3-chloro-4-fluoroaniline. The reaction mixture is refluxed for two hours under a nitrogen atmosphere. After cooling to room temperature, the resulting light precipitate is filtered off, washed with a little isopropanol and dried in air.
Yield: 4.99 g (92% of theory),
R f value: 0.80 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI + ): m / z = 430, 432 [M + H] +
Analog Beispiel II werden folgende Verbindungen erhalten:
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy-
7-methylcarbonyloxy-chinazolin
Rf-Wert: 0.86 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI+): m/z = 402, 404 [M+H]+
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-methylcarbonyloxy-chinazolin
Rf-Wert: 0.73 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 416, 418 [M+H]+
(3) 6-Benzyloxy-4-[(3-chlor-4-fluor-phenyl)amino]-7-methyl-
carbonyloxy-chinazolin
Rf-Wert: 0.76 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 438, 440 [M+H]+
(4) 4-[(3-Brom-phenyl)amino]-6-methylcarbonyloxy-7-methoxy-
chinazolin
Rf-Wert: 0.50 (Kieselgel, Essigester)
Massenspektrum (ESI+): m/z = 388, 390 [M+H]+
(5) 4-[(R)-(1-Phenyl-ethyl)amino]-6-hydroxy-7-methoxy-china
zolin (Die Acetoxy-Schutzgruppe wird unter den Reaktionsbe
dingungen bereits abgespalten)
Rf-Wert: 0.46 (Kieselgel, Essigester)
Massenspektrum (ESI+): m/z = 296 [M+H]+ The following compounds are obtained analogously to Example II:
(1) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopropylmethoxy-7-methylcarbonyloxy-quinazoline
R f value: 0.86 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI + ): m / z = 402, 404 [M + H] +
(2) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7-methylcarbonyloxy-quinazoline
R f value: 0.73 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass Spectrum (ESI + ): m / z = 416, 418 [M + H] +
(3) 6-Benzyloxy-4 - [(3-chloro-4-fluoro-phenyl) -amino] -7-methyl-carbonyloxy-quinazoline
R f value: 0.76 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI + ): m / z = 438, 440 [M + H] +
(4) 4 - [(3-Bromo-phenyl) -amino] -6-methylcarbonyloxy-7-methoxy-quinazoline
R f value: 0.50 (silica gel, ethyl acetate)
Mass Spectrum (ESI + ): m / z = 388, 390 [M + H] +
(5) 4 - [(R) - (1-phenylethyl) amino] -6-hydroxy-7-methoxy-china zoline (The acetoxy protecting group is already split off under the reaction conditions)
R f value: 0.46 (silica gel, ethyl acetate)
Mass spectrum (ESI + ): m / z = 296 [M + H] +
3.80 g 4-Hydroxy-6-cyclopentylmethoxy-7-methylcarbonyloxy-
chinazolin werden in 90 ml Thionylchlorid suspendiert und
unter Stickstoff-Atmosphäre zum Sieden erhitzt. Nach Zugabe
von vier Tropfen N,N-Dimethylformamid wird das Reaktionsge
misch noch zwei Stunden unter Rückfluß erhitzt. Nach Abkühlung
auf Raumtemperatur wird das überschüssige Thionylchlorid im
Wasserstrahlvakuum abdestilliert. Der braune Rückstand wird
mit 30 ml Toluol verrührt. Das Lösungsmittel wird abdestil
liert und es bleiben 4.30 g eines graubraunen Feststoffes
zurück, welcher ohne weitere Reinigung weiter umgesetzt wird.
Rf-Wert: 0.89 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
3.80 g of 4-hydroxy-6-cyclopentylmethoxy-7-methylcarbonyloxy-quinazoline are suspended in 90 ml of thionyl chloride and heated to boiling under nitrogen atmosphere. After addition of four drops of N, N-dimethylformamide, the reaction mixture is heated for a further two hours under reflux. After cooling to room temperature, the excess thionyl chloride is distilled off in a water-jet vacuum. The brown residue is stirred with 30 ml of toluene. The solvent is distilled off and 4.30 g of a gray-brown solid remain, which is reacted further without further purification.
R f value: 0.89 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Analog Beispiel IV werden folgende Verbindungen erhalten:
(1) 4-Chlor-6-cyclopropylmethoxy-7-methylcarbonyloxy-china
zolin
Rf-Wert: 0.84 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
(2) 4-Chlor-6-cyclopentyloxy-7-methylcarbonyloxy-chinazolin
Rf-Wert: 0.69 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
(3) 6-Benzyloxy-4-chlor-7-methylcarbonyloxy-chinazolin
Rf-Wert: 0.77 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)Analogously to Example IV, the following compounds are obtained:
(1) 4-Chloro-6-cyclopropylmethoxy-7-methylcarbonyloxy-china zolin
R f value: 0.84 (silica gel, methylene chloride / methanol = 9: 1)
(2) 4-Chloro-6-cyclopentyloxy-7-methylcarbonyloxy-quinazoline
R f value: 0.69 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
(3) 6-Benzyloxy-4-chloro-7-methylcarbonyloxy-quinazoline
R f value: 0.77 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
4.30 g 4,7-Dihydroxy-6-cyclopentylmethoxy-chinazolin in 100 ml
Pyridin werden unter Stickstoff-Atmosphäre auf 80°C erhitzt.
Zur dunkelbraunen Suspension werden 1.80 ml Essigsäureanhydrid
gegeben. Das Reaktionsgemisch wird drei Stunden bei 80°C ge
rührt, wobei eine vollständige Lösung entsteht. Nach Abkühlung
auf Raumtemperatur wird das Reaktionsgemisch auf ca. 800 ml
Eiswasser gegossen. Der entstandene Niederschlag wird abge
saugt und gründlich mit Wasser nachgewaschen. Der hellgraue
Feststoff wird im Vakuumexsikkator getrocknet.
Ausbeute: 3.82 g (77% der Theorie),
Rf-Wert: 0.49 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI-): m/z = 301 [M-H]- 4.30 g of 4,7-dihydroxy-6-cyclopentylmethoxy-quinazoline in 100 ml of pyridine are heated to 80 ° C. under a nitrogen atmosphere. 1.80 ml of acetic anhydride are added to the dark brown suspension. The reaction mixture is stirred for three hours at 80 ° C, whereby a complete solution is formed. After cooling to room temperature, the reaction mixture is poured onto about 800 ml of ice water. The resulting precipitate is filtered off and washed thoroughly with water. The light gray solid is dried in a vacuum desiccator.
Yield: 3.82 g (77% of theory),
R f value: 0.49 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI -): m / z = 301 [MH] -
Analog Beispiel V werden folgende Verbindungen erhalten:
(1) 4-Hydroxy-6-cyclopropylmethoxy-7-methylcarbonyloxy-china
zolin
Rf-Wert: 0.53 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI-): m/z = 273 [M-H]-
(2) 4-Hydroxy-6-cyclopentyloxy-7-methylcarbonyloxy-chinazolin
Schmelzpunkt: 209-212°C
Massenspektrum (ESI-): m/z = 287 [M-H]-
(3) 6-Benzyloxy-4-hydroxy-7-methylcarbonyloxy-chinazolin
Rf-Wert: 0.48 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI-): m/z = 309 [M-H]- Analogously to Example V, the following compounds are obtained:
(1) 4-Hydroxy-6-cyclopropylmethoxy-7-methylcarbonyloxy-china zolin
R f value: 0.53 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI - ): m / z = 273 [MH] -
(2) 4-hydroxy-6-cyclopentyloxy-7-methylcarbonyloxy-quinazoline
Melting point: 209-212 ° C
Mass spectrum (ESI -): m / z = 287 [MH] -
(3) 6-Benzyloxy-4-hydroxy-7-methylcarbonyloxy-quinazoline
R f value: 0.48 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI -): m / z = 309 [MH] -
5.76 g 2-Amino-5-cyclopentylmethoxy-4-hydroxy-benzoesäure und
6.52 g Formamidinacetat in 140 ml Ethanol werden ca. drei
Stunden unter Rückfluß erhitzt. Zur Aufarbeitung wird das
Reaktionsgemisch auf etwa 100 ml eingeengt und mit 300 ml
Eiswasser versetzt, wobei ein grauer Niederschlag ausfällt.
Der Niederschlag wird abgesaugt, mit Wasser nachgewaschen und
im Vakuumexsikkator getrocknet.
Ausbeute: 4.57 g (77% der Theorie),
Rf-Wert: 0.25 (Kieselgel, Methylenchlorid/Methanol = 95 : 5)
Massenspektrum (ESI-): m/z = 259 [M-H]- 5.76 g of 2-amino-5-cyclopentylmethoxy-4-hydroxybenzoic acid and 6.52 g of formamidine acetate in 140 ml of ethanol are refluxed for about three hours. For workup, the reaction mixture is concentrated to about 100 ml and treated with 300 ml of ice water, wherein a gray precipitate precipitates. The precipitate is filtered off with suction, washed with water and dried in a vacuum desiccator.
Yield: 4.57 g (77% of theory),
R f value: 0.25 (silica gel, methylene chloride / methanol = 95: 5)
Mass spectrum (ESI -): m / z = 259 [MH] -
Analog Beispiel VI werden folgende Verbindungen erhalten:
(1) 4,7-Dihydroxy-6-cyclopropylmethoxy-chinazolin
Rf-Wert: 0.45 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI-): m/z = 231 [M-H]-
(2) 4,7-Dihydroxy-6-cyclopentyloxy-chinazolin
Rf-Wert: 0.42 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (EI): m/z = 246 [M]+
(3) 6-Benzyloxy-4,7-dihydroxy-chinazolin
Rf-Wert: 0.44 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI-): m/z = 267 [M-H]- The following compounds are obtained analogously to Example VI:
(1) 4,7-Dihydroxy-6-cyclopropylmethoxy-quinazoline
R f value: 0.45 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI - ): m / z = 231 [MH] -
(2) 4,7-Dihydroxy-6-cyclopentyloxy-quinazoline
R f value: 0.42 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (EI): m / z = 246 [M] +
(3) 6-Benzyloxy-4,7-dihydroxy-quinazoline
R f value: 0.44 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI -): m / z = 267 [MH] -
6.50 g 5-Cyclopentylmethoxy-4-hydroxy-2-nitro-benzoesäure wer
den in 130 mL Methanol gelöst, mit 2.00 g Raney-Nickel ver
setzt und unter einem Wasserstoffdruck von 50 psi etwa drei
Stunden bei Raumtemperatur hydriert, bis die berechnete Menge
Wasserstoff aufgenommen ist. Der Katalysator wird abfiltriert
und mit heißem Methanol nachgewaschen. Das Filtrat wird im
Vakuum eingeengt. Es bleibt ein bräunlicher Feststoff zurück,
welcher ohne weitere Reinigung weiter umgesetzt wird.
Ausbeute: 5.79 g (100% der Theorie),
Rf-Wert: 0.67 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI-): m/z = 250 [M-H]- 6.50 g of 5-cyclopentylmethoxy-4-hydroxy-2-nitro-benzoic acid who dissolved in 130 mL of methanol, with 2.00 g Raney nickel ver and hydrogenated under a hydrogen pressure of 50 psi for about three hours at room temperature until the calculated amount of hydrogen is included. The catalyst is filtered off and washed with hot methanol. The filtrate is concentrated in vacuo. It remains a brownish solid back, which is further reacted without further purification.
Yield: 5.79 g (100% of theory),
R f value: 0.67 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI -): m / z = 250 [MH] -
Analog Beispiel VII werden folgende Verbindungen erhalten:
(1) 2-Amino-5-cyclopropylmethoxy-4-hydroxy-benzoesäure
Rf-Wert: 0.51 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI-): m/z = 222 [M-H]-
(2) 2-Amino-5-cyclopentyloxy-4-hydroxy-benzoesäure
Rf-Wert: 0.38 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 238 [M+H]+
(3) 2-Amino-5-benzyloxy-4-hydroxy-benzoesäure
Rf-Wert: 0.52 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI-): m/z = 258 [M-H]-
The following compounds are obtained analogously to Example VII:
(1) 2-Amino-5-cyclopropylmethoxy-4-hydroxybenzoic acid R f value: 0.51 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI - ): m / z = 222 [MH] -
(2) 2-Amino-5-cyclopentyloxy-4-hydroxybenzoic acid
R f value: 0.38 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI + ): m / z = 238 [M + H] +
(3) 2-Amino-5-benzyloxy-4-hydroxybenzoic acid
R f value: 0.52 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI -): m / z = 258 [MH] -
15.37 g 4,5-Methylendioxy-2-nitro-benzoesäure und 51.84 ml
Cyclopentylmethanol werden in 100 ml Dimethylsulfoxid gelöst
und unter Stickstoff-Atmosphäre im Eisbad abgekühlt. Nun wer
den portionsweise 3.90 g Natrium zugegeben. Das Reaktionsge
misch wird 30 Minuten unter Eisbad-Kühlung gerührt, dann kurz
zeitig auf 35-40°C erwärmt und anschließend noch weitere drei
Stunden unter Eisbad-Kühlung gerührt. Anschließend wird das
Eisbad entfernt und das Reaktionsgemisch über Nacht bei Raum
temperatur gerührt. Die dunkelbraunrote Reaktionslösung wird
auf ca. 800 ml Aceton gegossen, wobei ein dunkelbrauner Nie
derschlag ausfällt. Der Niederschlag wird abgesaugt, mit Ace
ton nachgewaschen, in 300-400 ml Wasser gelöst und mit 60 ml
2 N Salzsäure auf etwa pH 2 eingestellt. Die wäßrige Lösung
wird mehrmals mit Methylenchlorid extrahiert. Die vereinigten
Extrakte werden mit gesättigter Natriumchlorid-Lösung ge
waschen, über Natriumsulfat getrocknet und eingeengt. Der
dunkelbraune, ölige Kolbenrückstand wird in 800 ml Methylen
chlorid gelöst und über ein Kieselgelpackung mit Methylen
chlorid/Methanol (9 : 1) gereinigt. Man erhält ein braunes Öl,
welches durch verrühren mit Wasser unter Eisbad-Kühlung zur
Kristallisation gebracht wird. Der entstandene bräunliche
Niederschlag wird abgesaugt, mit wenig Wasser nachgewaschen
und im Vakuumexsikkator getrocknet.
Ausbeute: 9.55 g (47% der Theorie),
Rf-Wert: 0.67 (Kieselgel, Toluol/Dioxan/Ethanol/Eisessig =
90 : 10 : 10 : 6)
Massenspektrum (ESI-): m/z = 280 [M-H]-
15.37 g of 4,5-methylenedioxy-2-nitro-benzoic acid and 51.84 ml of cyclopentylmethanol are dissolved in 100 ml of dimethyl sulfoxide and cooled under a nitrogen atmosphere in an ice bath. Now who added the portionwise 3.90 g of sodium. The reaction mixture is stirred for 30 minutes under ice bath cooling, then briefly heated to 35-40 ° C and then stirred for a further three hours under ice-bath cooling. Then the ice bath is removed and the reaction mixture is stirred overnight at room temperature. The dark brown red reaction solution is poured onto about 800 ml of acetone, whereby a dark brown Never precipitate precipitates. The precipitate is filtered off with suction, washed with acetone, dissolved in 300-400 ml of water and adjusted to about pH 2 with 60 ml of 2N hydrochloric acid. The aqueous solution is extracted several times with methylene chloride. The combined extracts are washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated. The dark brown, oily flask residue is dissolved in 800 ml of methylene chloride and purified over a silica gel packing with methylene chloride / methanol (9: 1). A brown oil is obtained, which is made to crystallize by stirring with water under ice-bath cooling. The resulting brownish precipitate is filtered off with suction, washed with a little water and dried in a vacuum desiccator.
Yield: 9.55 g (47% of theory),
R f value: 0.67 (silica gel, toluene / dioxane / ethanol / glacial acetic acid = 90: 10: 10: 6)
Mass spectrum (ESI - ): m / z = 280 [MH] -
Analog Beispiel VIII werden folgende Verbindungen erhalten:
(1) 5-Cyclopropylmethoxy-4-hydroxy-2-nitro-benzoesäure
Rf-Wert: 0.61 (Kieselgel, Toluol/Dioxan/Ethanol/Eisessig =
90 : 10 : 10 : 6)
Massenspektrum (ESI-): m/z = 252 [M-H]-
(2) 5-Cyclopentyloxy-4-hydroxy-2-nitro-benzoesäure
Rf-Wert: 0.62 (Kieselgel, Toluol/Dioxan/Ethanol/Eisessig =
90 : 10 : 10 : 6)
Massenspektrum (ESI-): m/z = 266 [M-H]-
(3) 5-Benzyloxy-4-hydroxy-2-nitro-benzoesäure
Schmelzpunkt: 176-178°C
Massenspektrum (ESI-): m/z = 288 [M-H]- The following compounds are obtained analogously to Example VIII:
(1) 5-Cyclopropylmethoxy-4-hydroxy-2-nitrobenzoic acid
R f value: 0.61 (silica gel, toluene / dioxane / ethanol / glacial acetic acid = 90: 10: 10: 6)
Mass spectrum (ESI -): m / z = 252 [MH] -
(2) 5-Cyclopentyloxy-4-hydroxy-2-nitrobenzoic acid
R f value: 0.62 (silica gel, toluene / dioxane / ethanol / glacial acetic acid = 90: 10: 10: 6)
Mass spectrum (ESI -): m / z = 266 [MH] -
(3) 5-Benzyloxy-4-hydroxy-2-nitrobenzoic acid
Melting point: 176-178 ° C
Mass spectrum (ESI -): m / z = 288 [MH] -
Zu 50.00 g Glycinethylester-hydrochlorid in 100 ml gesättigter
Kaliumcarbonat-Lösung werden unter Kühlung 100.00 g Natrium
carbonat gegeben. Die entstandene Masse wird mehrmals mit ins
gesamt ca. 600 ml Diethylether extrahiert. Die vereinigten
Etherextrakte werden über Natriumsulfat getrocknet und zur
Trockne eingeengt. Es bleiben 28.60 g Glycinethylester zurück.
Dieser wird mit 26.00 ml Isobutylenoxid und 40 ml absolutem
Ethanol versetzt und in einer Roth-Bombe sechs Stunden auf
90°C erhitzt. Nach Abkühlung auf Raumtemperatur wird das Reak
tionsgemisch eingeengt, wobei ein dünnflüssiges Öl zurück
bleibt.
Ausbeute: 45.80 g (73% der Theorie),
Massenspektrum (ESI+): m/z = 176 [M+H]+
100.00 g of sodium carbonate are added with cooling to 50.00 g of glycine ethyl ester hydrochloride in 100 ml of saturated potassium carbonate solution. The resulting mass is extracted several times with a total of about 600 ml of diethyl ether. The combined ether extracts are dried over sodium sulfate and concentrated to dryness. There remain 28.60 g of glycine ethyl ester. This is mixed with 26.00 ml of isobutylene oxide and 40 ml of absolute ethanol and heated in a Roth bomb at 90 ° C for six hours. After cooling to room temperature, the reac tion mixture is concentrated, leaving a thin liquid oil remains.
Yield: 45.80 g (73% of theory), mass spectrum (ESI + ): m / z = 176 [M + H] +
2.00 g 4-(N-Benzyl-N-methyl-amino)-dihydrofuran-2-on in
25 ml Methanol werden in Gegenwart von 250 mg Palladium (10%ig
auf Aktivkohle) bei einem Wasserstoffdruck von 50 psi ca. zwei
Stunden bei Raumtemperatur hydriert, bis die berechnete Menge
Wasserstoff aufgenommen ist. Zur Aufarbeitung wird der Kata
lysator abfiltriert und das Filtrat im Vakuum eingeengt. Es
bleibt ein farbloses Öl zurück, welches ohne weitere Reinigung
sofort weiter umgesetzt wird.
Ausbeute: 1.20 g
Rf-Wert: 0.13 (Kieselgel, Essigester)
Massenspektrum (ESI+): m/z = 116 [M+H]+ 2.00 g of 4- (N-benzyl-N-methyl-amino) -dihydrofuran-2-one in 25 ml of methanol in the presence of 250 mg of palladium (10% on activated carbon) at a hydrogen pressure of 50 psi for about two hours Room temperature hydrogenated until the calculated amount of hydrogen is absorbed. For workup, the Kata analyzer is filtered off and the filtrate concentrated in vacuo. It remains a colorless oil, which is reacted immediately without further purification.
Yield: 1.20 g
R f value: 0.13 (silica gel, ethyl acetate)
Mass spectrum (ESI + ): m / z = 116 [M + H] +
Zu 15.00 g 5H-Furan-2-on in 150 ml Methylenchlorid werden
23.20 ml N-Methylbenzylamin gegeben. Das Reaktionsgemisch wird
ca. 48 Stunden bei Raumtemperatur gerührt. Zur Aufarbeitung
wird das Reaktionsgemisch eingeengt und portionsweise über
eine Kieselgelsäule mit Essigester/Petrolether (3 : 1) als
Laufmittel chromatographiert. Das gewünschte Produkt wird als
gelbliches Öl erhalten.
Ausbeute: 19.77 g (54% der Theorie),
Rf-Wert: 0.67 (Kieselgel, Essigester)
Massenspektrum (ESI+): m/z = 228 [M+Na]+ To 15.00 g of 5H-furan-2-one in 150 ml of methylene chloride are added 23.20 ml of N-methylbenzylamine. The reaction mixture is stirred for about 48 hours at room temperature. For workup, the reaction mixture is concentrated and chromatographed in portions over a silica gel column with ethyl acetate / petroleum ether (3: 1) as the eluent. The desired product is obtained as a yellowish oil.
Yield: 19.77 g (54% of theory),
R f value: 0.67 (silica gel, ethyl acetate)
Mass spectrum (ESI + ): m / z = 228 [M + Na] +
Zu 5.60 g 6-Benzyloxy-4-[(3-chlor-4-fluor-phenyl)amino]-
7-cyclobutyloxy-chinazolin werden unter Rühren 10 ml Tri
fluoressigsäure getropft. Das Reaktionsgemisch erwärmt sich
dabei auf ca. 40°C. Nach 20 Stunden Rühren bei Raumtemperatur
werden nochmals 3 ml Trifluoressigsäure zugesetzt. Nachdem die
Umsetzung auch nach weiteren drei Stunden Rühren bei Raumtem
petatur kaum vorangeschritten ist, wird das Reaktionsgemisch
auf 50°C erwärmt. Nach vier Stunden ist die Umsetzung voll
ständig und die überschüssige Trifluoressigsäure wird am Ro
tationsverdampfer weitgehend abdestilliert. Der Rückstand wird
mit Wasser versetzt und mit konzentrierter, wäßriger Ammoniak
lösung alkalisch gestellt. Der entstandene hellbraune Nieder
schlag wird abgesaugt, mit reichlich Wasser nachgewaschen und
im Exsikkator getrocknet. Das erhaltene Produkt enthält noch
Trifluoressigsäure.
Ausbeute: 5.82 g
Rf-Wert: 0.61 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI+): m/z = 360, 362 [M+H]+ To 5.60 g of 6-benzyloxy-4 - [(3-chloro-4-fluoro-phenyl) amino] - 7-cyclobutyloxy-quinazoline are added dropwise with stirring 10 ml of trifluoroacetic acid. The reaction mixture is heated to about 40 ° C. After stirring for 20 hours at room temperature, another 3 ml of trifluoroacetic acid are added. After the reaction has hardly progressed even after stirring for a further three hours in Raumtem petatur, the reaction mixture is heated to 50 ° C. After four hours, the reaction is fully continuous and the excess trifluoroacetic acid is largely distilled off on Ro tationsverdampfer. The residue is mixed with water and made alkaline with concentrated aqueous ammonia solution. The resulting light brown precipitate is filtered off, washed with plenty of water and dried in a desiccator. The product obtained still contains trifluoroacetic acid.
Yield: 5.82 g
R f value: 0.61 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI + ): m / z = 360, 362 [M + H] +
Analog Beispiel XII werden folgende Verbindungen erhalten:
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclopropylmethoxy-
6-hydroxy-chinazolin
Rf-Wert: 0.65 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI+): m/z = 360, 362 [M+H]+ The following compounds are obtained analogously to Example XII:
(1) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -7-cyclopropylmethoxy-6-hydroxy-quinazoline
R f value: 0.65 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI + ): m / z = 360, 362 [M + H] +
Zu 7.00 g 6-Benzyloxy-4-[(3-chlor-4-fluor-phenyl)amino]-7-hy
droxy-chinazolin in 60 ml N,N-Dimethylformamid werden 7.50 g
Kaliumcarbonat und 4.50 g Methansulfonsäure-cyclobutylester
gegeben. Das Reaktionsgemisch wird zwei Stunden bei 80°C
gerührt. Dann werden nochmals 2.00 g Methansulfonsäure-cyclo
butylester und 3.00 g Kaliumcarbonat zugesetzt und das Gemisch
wird übers Wochenende bei 60°C gerührt. Da die Umsetzung immer
noch nicht vollständig ist, werden erneut 3.50 g Methansulfon
säure-cyclobutylester und 5.00 g Kaliumcarbonat zugegeben.
Nach weiteren 20 Stunden bei 80°C ist die Umsetzung nahezu
vollständig. Zur Aufarbeitung wird das Reaktionsgemisch mit
300 ml Essigester versetzt und mit Wasser und gesättigter
Natriumchlorid-Lösung gewaschen. Die organische Phase wird
über Magnesiumsulfat getrocknet und eingeengt. Der Rückstand
wird mit Methanol verrührt, wobei ein bräunlicher Niederschlag
entsteht. Dieser wird abgesaugt, mit Methanol nachgewaschen
und im Exsikkator getrocknet.
Ausbeute: 5.10 g (64% der Theorie),
Rf-Wert: 0.69 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI-): m/z = 448, 450 [M-H]- To 7.00 g of 6-benzyloxy-4 - [(3-chloro-4-fluorophenyl) amino] -7-hydroxy-quinazoline in 60 ml of N, N-dimethylformamide are added 7.50 g of potassium carbonate and 4.50 g of methanesulfonic acid cyclobutylester. The reaction mixture is stirred for two hours at 80.degree. Then another 2.00 g of methanesulfonic acid cyclo butyl ester and 3.00 g of potassium carbonate are added and the mixture is stirred at 60 ° C over the weekend. Since the reaction is still not complete, 3.50 g of methanesulfonic acid cyclobutylester and 5.00 g of potassium carbonate are added again. After a further 20 hours at 80 ° C, the reaction is almost complete. For workup, the reaction mixture is mixed with 300 ml of ethyl acetate and washed with water and saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and concentrated. The residue is stirred with methanol to give a brownish precipitate. This is filtered off, washed with methanol and dried in a desiccator.
Yield: 5.10 g (64% of theory),
R f value: 0.69 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI -): m / z = 448, 450 [MH] -
Analog Beispiel XIII werden folgende Verbindungen erhalten:
(1) 6-Benzyloxy-4-[(3-chlor-4-fluor-phenyl)amino]-7-cyclo
propylmethoxy-chinazolin (Es wird Brommethylcyclopropan
eingesetzt)
Rf-Wert: 0.72 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI-): m/z = 448, 450 [M-H]- The following compounds are obtained analogously to Example XIII:
(1) 6-Benzyloxy-4 - [(3-chloro-4-fluoro-phenyl) -amino] -7-cyclopropylmethoxy-quinazoline (bromomethylcyclopropane is used)
R f value: 0.72 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI -): m / z = 448, 450 [MH] -
15.00 g (S)-(+)-1-Amino-2-propanol werden in 100 ml N,N-Di
methylformamid gelöst und mit 6.97 ml Diisopropylethylamin
versetzt. Dann werden unter Eisbad-Kühlung 5.91 ml Brom
essigsäure-tert.butylester innerhalb von 30 Minuten zuge
tropft. Das Kühlbad wird entfernt und Reaktionsgemisch wird
über Nacht bei Raumtemperatur gerührt. Zur Aufarbeitung wird
das Reaktionsgemisch im Vakuum eingeengt. Der Kolbenrückstand
wird in 50 ml Wasser gelöst und mit 15 g Natriumchlorid ge
sättigt. Die wäßrige Lösung wird mehrmals mit Essigester ex
trahiert. Die vereinten Extrakte werden mit gesättigter Na
triumchlorid-Lösung gewaschen, über Magnesiumsulfat getrocknet
und im Vakuum eingeengt, wobei ein gelbliches Öl zurückbleibt.
Ausbeute: 7.36 g (97% der Theorie),
Rf-Wert: 0.46 (Kieselgel, Essigester/Methanol = 9 : 1)
Massenspektrum (ESI+): m/z = 190 [M+H]+ 15.00 g of (S) - (+) - 1-amino-2-propanol are dissolved in 100 ml of N, N-Di methylformamide and treated with 6.97 ml of diisopropylethylamine. Then 5.91 ml bromoacetic acid tert.butylester are added dropwise within 30 minutes under ice bath cooling. The cooling bath is removed and reaction mixture is stirred overnight at room temperature. For workup, the reaction mixture is concentrated in vacuo. The flask residue is dissolved in 50 ml of water and saturated with 15 g of sodium chloride ge. The aqueous solution is extracted several times with ethyl acetate ex tracted. The combined extracts are washed with saturated Na triumchlorid solution, dried over magnesium sulfate and concentrated in vacuo, leaving a yellowish oil remains.
Yield: 7.36 g (97% of theory),
R f value: 0.46 (silica gel, ethyl acetate / methanol = 9: 1)
Mass spectrum (ESI + ): m / z = 190 [M + H] +
Analog Beispiel XIV werden folgende Verbindungen erhalten:
(1) (R)-(2-Hydroxy-propylamino)-essigsäure-tert.butylester
Rf-Wert: 0.46 (Kieselgel, Essigester/Methanol = 9 : 1)
Massenspektrum (ESI+): m/z = 190 [M+H]+
The following compounds are obtained analogously to Example XIV:
(1) (R) - (2-Hydroxy-propylamino) -acetic acid-tert-butyl ester
R f value: 0.46 (silica gel, ethyl acetate / methanol = 9: 1)
Mass spectrum (ESI + ): m / z = 190 [M + H] +
250 mg 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentylmethoxy-
7-(2-brom-ethoxy)-chinazolin und 341 mg (2-Hydroxy-2-methyl-
propylamino)-essigsäure-ethylester werden in 20 ml Acetonitril
gelöst und mit 50 mg Natriumiodid, 275 mg Kaliumcarbonat und
0.70 ml Diisopropylethylamin versetzt. Das Reaktionsgemisch
wird ca. 90 Stunden unter Rückfluß erhitzt. Nach Abkühlung auf
Raumtemperatur wird das Reaktionsgemisch filtriert und das
Filtrat im Vakuum eingeengt. Der Kolbenrückstand wird über
eine Kieselgelsäule mit Petrolether/Essigester (50 : 50, später
0 : 100) als Laufmittel chromatographiert. Man erhält das cycli
sierte Produkt als beigefarbenen Feststoff.
Ausbeute: 62 mg (23% der Theorie),
Rf-Wert: 0.29 (Kieselgel, Essigester)
Massenspektrum (ESI-): m/z = 541, 543 [M-H]- 250 mg of 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentylmethoxy-7- (2-bromo-ethoxy) -quinazoline and 341 mg of (2-hydroxy-2-methyl-propylamino) -acetic acid Ethyl acetate are dissolved in 20 ml of acetonitrile and treated with 50 mg of sodium iodide, 275 mg of potassium carbonate and 0.70 ml of diisopropylethylamine. The reaction mixture is refluxed for about 90 hours. After cooling to room temperature, the reaction mixture is filtered and the filtrate is concentrated in vacuo. The flask residue is chromatographed on a silica gel column with petroleum ether / ethyl acetate (50:50, later 0: 100) as the eluent. The cyclized product is obtained as a beige solid.
Yield: 62 mg (23% of theory),
R f value: 0.29 (silica gel, ethyl acetate)
Mass spectrum (ESI - ): m / z = 541, 543 [MH] -
Analog Beispiel 1 werden folgende Verbindungen erhalten:
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy-
7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-chinazolin
Rf-Wert: 0.58 (Kieselgel, Methylenchlorid/Methanol = 9 : 1)
Massenspektrum (ESI-): m/z = 513, 515 [M-H]-
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclobutyloxy-
6-[3-(2,2-dimethyl-6-oxo-morpholin-4-yl)-propyloxy]-chinazolin
Schmelzpunkt: 212-214°C
Massenspektrum (ESI-): m/z = 527, 529 [M-H]-
(3) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclopropylmethoxy-
6-[3-(2,2-dimethyl-6-oxo-morpholin-4-yl)-propyloxy]-chinazolin
Schmelzpunkt: 200-202°C
Massenspektrum (ESI-): m/z = 527, 529 [M-H]- Analogously to Example 1, the following compounds are obtained:
(1) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopropylmethoxy-7- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] - quinazoline
R f value: 0.58 (silica gel, methylene chloride / methanol = 9: 1)
Mass spectrum (ESI -): m / z = 513, 515 [MH] -
(2) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -7-cyclobutyloxy-6- [3- (2,2-dimethyl-6-oxo-morpholin-4-yl) -propyloxy] - quinazoline
Melting point: 212-214 ° C
Mass spectrum (ESI - ): m / z = 527, 529 [MH] -
(3) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -7-cyclopropylmethoxy-6- [3- (2,2-dimethyl-6-oxomorpholin-4-yl) -propyloxy] - quinazoline
Melting point: 200-202 ° C
Mass spectrum (ESI - ): m / z = 527, 529 [MH] -
300 mg 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy-
7-(2-brom-ethoxy)-chinazolin und 400 mg 4-Methylamino-dihydro
furan-2-on in 20 ml Acetonitril werden mit 240 mg Kaliumcar
bonat und 70 mg Natriumiodid versetzt und 24 Stunden unter
Rückfluß erhitzt. Nach Abkühlung auf Raumtemperatur wird das
Reaktionsgemisch filtriert und das Filtrat im Vakuum einge
engt. Der Kolbenrückstand wird über eine Kieselgelsäule mit
Methylenchlorid/Methanol/konzentrierter, wäßriger Ammoniak
lösung (97 : 3 : 0.05) als Laufmittel chromatographiert. Die
Titelverbindung wird als hellbeigefarbener Feststoff erhalten.
Ausbeute: 70 mg (22% der Theorie),
Rf-Wert: 0.47 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 501, 503 [M+H]+ 300 mg of 4 - [(3-chloro-4-fluorophenyl) amino] -6-cyclopropylmethoxy-7- (2-bromoethoxy) quinazoline and 400 mg of 4-methylamino-dihydro-furan-2-one in 20 ml Acetonitrile are mixed with 240 mg Kaliumcar carbonate and 70 mg of sodium iodide and heated for 24 hours under reflux. After cooling to room temperature, the reaction mixture is filtered and the filtrate concentrated in vacuo. The flask residue is chromatographed on a silica gel column with methylene chloride / methanol / concentrated aqueous ammonia solution (97: 3: 0.05) as the eluent. The title compound is obtained as a light beige solid.
Yield: 70 mg (22% of theory),
R f value: 0.47 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass spectrum (ESI + ): m / z = 501, 503 [M + H] +
Analog Beispiel 2 werden folgende Verbindungen erhalten:
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy-
7-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-N-methyl-amino]-ethoxy}-
chinazolin
Rf-Wert: 0.42 (Kieselgel, Methylenchlorid/Methanol/konzentrier
te, wäßrige Ammoniaklösung = 90 : 10 : 0.1)
Massenspektrum (ESI+): m/z = 515, 517 [M+H]+
Analogously to Example 2, the following compounds are obtained:
(1) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} - quinazoline
R f value: 0.42 (silica gel, methylene chloride / methanol / concentrated te, aqueous ammonia solution = 90: 10: 0.1)
Mass Spectrum (ESI + ): m / z = 515, 517 [M + H] +
Zu 380 mg 4-[(3-Brom-phenyl)amino]-6-(2-{N-[(tert.butyloxycar
bonyl)methyl]-N-((S)-2-hydroxy-propyl)-amino}-ethoxy)-7-meth
oxy-chinazolin in 8 ml Acetonitril werden 90 µl Methansulfon
säure gegeben. Das Reaktionsgemisch wird ca. drei Stunden
unter Rückfluß erhitzt, dann wird nochmals ein Äquivalent Me
thansulfonsäure zugegeben und weiter unter Rückfluß erhitzt,
bis die Umsetzung vollständig ist. Zur Aufarbeitung wird das
Reaktionsgemisch mit Essigester verdünnt und mit gesättigter
Natriumhydrogencarbonat-Lösung und gesättigter Natriumchlorid-
Lösung gewaschen. Die organische Phase wird über Magnesium
sulfat getrocknet und im Vakuum eingeengt. Der Kolbenrückstand
wird mit Diethylether verrührt und abgesaugt. Man erhält die
Titelverbindung als weißen Feststoff.
Ausbeute: 280 mg (85% der Theorie),
Schmelzpunkt: 190°C
Massenspektrum (ESI-): m/z = 485, 487 [M-H]- To 380 mg of 4 - [(3-bromo-phenyl) -amino] -6- (2- {N - [(tert-butyl-oxo-carbonyl) -methyl] -N - ((S) -2-hydroxy-propyl) -amino} -ethoxy) -7-methoxy-quinazoline in 8 ml of acetonitrile are added to 90 ul of methanesulfonic acid. The reaction mixture is refluxed for about three hours, then another equivalent of Me sulfonic acid is added and further heated to reflux until the reaction is complete. For workup, the reaction mixture is diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and concentrated in vacuo. The flask residue is stirred with diethyl ether and filtered with suction. The title compound is obtained as a white solid.
Yield: 280 mg (85% of theory),
Melting point: 190 ° C
Mass spectrum (ESI -): m / z = 485, 487 [MH] -
Analog Beispiel 3 werden folgende Verbindungen erhalten:
(1) 4-[(3-Brom-phenyl)amino]-6-[2-((R)-6-methyl-2-oxo-morpho
lin-4-yl)-ethoxy]-7-methoxy-chinazolin
Schmelzpunkt: 193°C
Massenspektrum (ESI+): m/z = 487, 489 [M+H]+
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-((R)-6-methyl-
2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin (Die
Reaktion wird mit Trifluoressigsäure in Acetonitril
durchgeführt)
Schmelzpunkt: 208°C
Massenspektrum (ESI-): m/z = 459, 461 [M-H]-
(3) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-((R)-6-methyl-
2-oxo-morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin (Die
Reaktion wird mit Trifluoressigsäure in Acetonitril durchge
führt)
Rf-Wert: 0.33 (Kieselgel, Essigester)
Massenspektrum (ESI-): m/z = 473, 475 [M-H]-
(4) 4-[(R)-(1-Phenyl-ethyl)amino]-6-[3-((S)-6-methyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin (Die Reaktion
wird mit Trifluoressigsäure in Acetonitril durchgeführt)
Rf-Wert: 0.41 (Kieselgel, Essigester/Methanol = 9 : 1)
Massenspektrum (ESI-): m/z = 449 [M-H]-
(5) 4-[(R)-(1-Phenyl-ethyl)amino]-6-[2-((S)-6-methyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin (Die Reaktion
wird mit Trifluoressigsäure in Acetonitril durchgeführt)
Rf-Wert: 0.49 (Kieselgel, Essigester/Methanol/konzentrierte,
wäßrige Ammoniaklösung = 9 : 1 : 0.1)
Massenspektrum (ESI-): m/z = 435 [M-H]- Analogously to Example 3, the following compounds are obtained:
(1) 4 - [(3-Bromo-phenyl) -amino] -6- [2 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline
Melting point: 193 ° C
Mass spectrum (ESI + ): m / z = 487, 489 [M + H] +
(2) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7- methoxy quinazoline (The reaction is carried out with trifluoroacetic acid in acetonitrile)
Melting point: 208 ° C
Mass spectrum (ESI -): m / z = 459, 461 [MH] -
(3) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -propyloxy] -7- methoxy quinazoline (The reaction is carried out with trifluoroacetic acid in acetonitrile)
R f value: 0.33 (silica gel, ethyl acetate)
Mass spectrum (ESI - ): m / z = 473, 475 [MH] -
(4) 4 - [(R) - (1-phenylethyl) amino] -6- [3 - ((S) -6-methyl-2-oxomorpholin-4-yl) -propyloxy] -7- methoxy quinazoline (The reaction is carried out with trifluoroacetic acid in acetonitrile)
R f value: 0.41 (silica gel, ethyl acetate / methanol = 9: 1)
Mass spectrum (ESI -): m / z = 449 [MH] -
(5) 4 - [(R) - (1-phenylethyl) amino] -6- [2 - ((S) -6-methyl-2-oxomorpholin-4-yl) -ethoxy] -7- methoxy quinazoline (The reaction is carried out with trifluoroacetic acid in acetonitrile)
R f value: 0.49 (silica gel, ethyl acetate / methanol / concentrated, aqueous ammonia solution = 9: 1: 0.1)
Mass spectrum (ESI -): m / z = 435 [MH] -
Zu 650 mg 4-[(3-Brom-phenyl)amino]-6-(2-brom-ethoxy)-7-meth
oxy-chinazolin und 1.10 g (S)-(2-Hydroxy-propylamino)-essig
säure-tert.butylester in 15 ml Acetonitril werden 0.25 ml Di
isopropylethylamin gegeben. Das Reaktionsgemisch wird über
Nacht bei 50°C gerührt. Da keine Umsetzung erkennbar ist, wird
das Reaktionsgemisch eingeengt, mit 20 ml N,N-Dimethylformamid
versetzt und acht Stunden bei 60°C gerührt. Anschließend wird
die Temperatur auf 80°C erhöht. Nach weiteren acht Stunden ist
die Umsetzung vollständig. Das Reaktionsgemisch wird eingeengt
und über eine Kieselgelsäule mit Essigester als Laufmittel
chromatographiert. Man erhält das gewünschte Produkt als
weißen Feststoff.
Ausbeute: 410 mg (51% der Theorie),
Rf-Wert: 0.27 (Kieselgel, Essigester)
Massenspektrum (ESI-): m/z = 559, 561 [M-H]- To 650 mg of 4 - [(3-bromophenyl) amino] -6- (2-bromoethoxy) -7-methoxyquinazoline and 1.10 g of (S) - (2-hydroxypropylamino) acetic acid tert-butyl ester in 15 ml of acetonitrile are added 0.25 ml of diisopropylethylamine. The reaction mixture is stirred overnight at 50.degree. Since no reaction is recognizable, the reaction mixture is concentrated, treated with 20 ml of N, N-dimethylformamide and stirred at 60 ° C for eight hours. Then the temperature is raised to 80 ° C. After another eight hours, the implementation is complete. The reaction mixture is concentrated and chromatographed on a silica gel column with ethyl acetate as the eluent. The desired product is obtained as a white solid.
Yield: 410 mg (51% of theory),
R f value: 0.27 (silica gel, ethyl acetate)
Mass spectrum (ESI - ): m / z = 559, 561 [MH] -
Analog Beispiel 4 werden folgende Verbindungen erhalten:
(1) 4-[(3-Brom-phenyl)amino]-6-(2-{N-[(tert.butyloxycarbonyl)-
methyl]-N-((R)-2-hydroxy-propyl)-amino}-ethoxy)-7-methoxy-
chinazolin
Schmelzpunkt: 130°C
Massenspektrum (ESI-): m/z = 559, 561 [M-H]-
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-(2-{N-[(tert.butyloxy
carbonyl)methyl]-N-((R)-2-hydroxy-propyl)-amino}-ethoxy)-
7-methoxy-chinazolin (Die Reaktion wird in N,N-Dimethylform
amid durchgeführt)
Rf-Wert: 0.40 (Kieselgel, Essigester/Petrolether = 4 : 1)
(3) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-(3-{N-[(tert.butyloxy
carbonyl)methyl]-N-((R)-2-hydroxy-propyl)-amino}-propyloxy)-
7-methoxy-chinazolin (Die Reaktion wird in N,N-Dimethylform
amid durchgeführt)
Rf-Wert: 0.37 (Kieselgel, Essigester/Petrolether = 4 : 1)
Massenspektrum (ESI-): m/z = 547, 549 [M-H]-
(4) 4-[(R)-(1-Phenyl-ethyl)amino]-6-(3-{N-[(tert.butyloxycar
bonyl)methyl]-N-((S)-2-hydroxy-propyl)-amino}-propyloxy)-
7-methoxy-chinazolin (Die Reaktion wird in N,N-Dimethylform
amid durchgeführt)
Rf-Wert: 0.65 (Kieselgel, Essigester/Methanol = 9 : 1)
Massenspektrum (EI): m/z = 524 [M]+
(5) 4-[(R)-(1-Phenyl-ethyl)amino]-6-(2-{N-[(tert.butyloxy
carbonyl)methyl]-N-((S)-2-hydroxy-propyl)-amino}-ethoxy)-
7-methoxy-chinazolin (Die Reaktion wird in N,N-Dimethylform
amid durchgeführt)
Rf-Wert: 0.57 (Kieselgel, Essigester/Methanol/konzentrierte,
wäßrige Ammoniaklösung = 9 : 1 : 0.1)The following compounds are obtained analogously to Example 4:
(1) 4 - [(3-Bromo-phenyl) -amino] -6- (2- {N - [(tert -butyloxycarbonyl) -methyl] -N - ((R) -2-hydroxy-propyl) -amino} -ethoxy) -7-methoxy-quinazoline
Melting point: 130 ° C
Mass spectrum (ESI - ): m / z = 559, 561 [MH] -
(2) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (2- {N - [(tert -butyloxy-carbonyl) -methyl] -N - ((R) -2-hydroxy-propyl ) -amino} -ethoxy) - 7-methoxy-quinazoline (The reaction is carried out in N, N-dimethylformamide)
R f value: 0.40 (silica gel, ethyl acetate / petroleum ether = 4: 1)
(3) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (3- {N - [(tert -butyloxy-carbonyl) -methyl] -N - ((R) -2-hydroxy-propyl ) -amino} -propyloxy) - 7-methoxy-quinazoline (The reaction is carried out in N, N-dimethylformamide)
R f value: 0.37 (silica gel, ethyl acetate / petroleum ether = 4: 1)
Mass spectrum (ESI - ): m / z = 547, 549 [MH] -
(4) 4 - [(R) - (1-Phenyl-ethyl) amino] -6- (3- {N - [(tert-butyl-oxycarbonyl) -methyl] -N - ((S) -2-hydroxy-propyl ) -amino} -propyloxy) - 7-methoxy-quinazoline (The reaction is carried out in N, N-dimethylformamide)
R f value: 0.65 (silica gel, ethyl acetate / methanol = 9: 1)
Mass spectrum (EI): m / z = 524 [M] +
(5) 4 - [(R) - (1-Phenylethyl) amino] -6- (2- {N - [(tert -butyloxy-carbonyl) -methyl] -N - ((S) -2-hydroxy-propyl ) -amino} -ethoxy) - 7-methoxy-quinazoline (The reaction is carried out in N, N-dimethylformamide)
R f value: 0.57 (silica gel, ethyl acetate / methanol / concentrated, aqueous ammonia solution = 9: 1: 0.1)
Analog den vorstehenden Beispielen und anderen literaturbe
kannten Verfahren können folgende Verbindungen hergestellt
werden:
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6-methyl-2-oxo-
morpholin-4-yl)-ethoxy]-6-methoxy-chinazolin
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6-methyl-2-oxo-
morpholin-4-yl)-propyloxy]-6-methoxy-chinazolin
(3) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-((S)-6-methyl-
2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin
(4) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-((S)-6-methyl-
2-oxo-morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin
(5) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(5,5-dimethyl-
2-oxo-morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin
(6) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(5,5-dimethyl-
2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin
(7) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(3-methyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin
(8) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(3-methyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin
(9) 4-[(R)-(1-Phenyl-ethyl)amino]-6-[3-((R)-6-methyl-2-oxo-
morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin
(10) 4-[(R)-(1-Phenyl-ethyl)amino]-6-[2-((R)-6-methyl-2-oxo-
morpholin-4-yl)-ethoxy]-7-methoxy-chinazolinAnalogously to the above examples and other methods known from the literature, the following compounds can be prepared:
(1) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6-methyl-2-oxomorpholin-4-yl) -ethoxy] -6-methoxy-quinazoline
(2) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -7- [3- (6-methyl-2-oxomorpholin-4-yl) -propyloxy] -6-methoxy-quinazoline
(3) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2 - ((S) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7- methoxy-quinazoline
(4) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3 - ((S) -6-methyl-2-oxo-morpholin-4-yl) -propyloxy] -7- methoxy-quinazoline
(5) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (5,5-dimethyl-2-oxo-morpholin-4-yl) -propyloxy] -7-methoxy quinazoline
(6) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy quinazoline
(7) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- [3- (3-methyl-2-oxomorpholin-4-yl) -propyloxy] -7-methoxy-quinazoline
(8) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline
(9) 4 - [(R) - (1-phenylethyl) amino] -6- [3 - ((R) -6-methyl-2-oxomorpholin-4-yl) -propyloxy] -7- methoxy-quinazoline
(10) 4 - [(R) - (1-phenylethyl) amino] -6- [2 - ((R) -6-methyl-2-oxomorpholin-4-yl) -ethoxy] -7- methoxy-quinazoline
Die Wirksubstanz wird mit Calciumphosphat, Maisstärke,
Polyvinylpyrrolidon, Hydroxypropylmethylcellulose und der
Hälfte der angegebenen Menge Magnesiumstearat gemischt. Auf
einer Tablettiermaschine werden Preßlinge mit einem
Durchmesser von ca. 13 mm hergestellt, diese werden auf einer
geeigneten Maschine durch ein Sieb mit 1,5 mm-Maschenweite
gerieben und mit der restlichen Menge Magnesiumstearat
vermischt. Dieses Granulat wird auf einer Tablettiermaschine
zu Tabletten mit der gewünschten Form gepreßt.
Kerngewicht: 230 mg
Stempel: 9 mm, gewölbt
The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half of the stated amount of magnesium stearate. On a tabletting machine compacts are produced with a diameter of about 13 mm, these are ground on a suitable machine through a sieve with a mesh size of 1.5 mm and mixed with the remaining amount of magnesium stearate. This granulate is pressed on a tabletting machine into tablets of the desired shape.
Core weight: 230 mg
Stamp: 9 mm, curved
Die so hergestellten Dragéekerne werden mit einem Film
überzogen, der im wesentlichen aus
Hydroxypropylmethylcellulose besteht. Die fertigen Filmdragées
werden mit Bienenwachs geglänzt.
Dragéegewicht: 245 mg.The thus prepared dragee cores are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished Filmdragées are shined with beeswax.
Dragée weight: 245 mg.
Wirkstoff, Milchzucker und Stärke werden gemischt und mit
einer wäßrigen Lösung des Polyvinylpyrrolidons gleichmäßig
befeuchtet. Nach Siebung der feuchten Masse (2,0 mm-
Maschenweite) und Trocknen im Hordentrockenschrank bei 50°C
wird erneut gesiebt (1,5 mm-Maschenweite) und das
Schmiermittel zugemischt. Die preßfertige Mischung wird zu
Tabletten verarbeitet.
Tablettengewicht: 220 mg
Durchmesser: 10 mm, biplan mit beidseitiger Facette und
einseitiger Teilkerbe.
Active ingredient, lactose and starch are mixed and uniformly moistened with an aqueous solution of polyvinylpyrrolidone. After screening of the moist mass (2.0 mm mesh size) and drying in a rack oven at 50 ° C is again sieved (1.5 mm mesh size) and admixed with the lubricant. The ready-to-use mixture is processed into tablets.
Tablet weight: 220 mg
Diameter: 10 mm, biplan with facet on both sides and one-sided part notch.
Die mit Milchzucker, Maisstärke und Kieselsäure gemischte
Wirksubstanz wird mit einer 20%igen wäßrigen Polyvinylpyr
rolidonlösung befeuchtet und durch ein Sieb mit 1,5 mm-Ma
schenweite geschlagen.
Das bei 45°C getrocknete Granulat wird nochmals durch dasselbe
Sieb gerieben und mit der angegebenen Menge Magnesiumstearat
gemischt. Aus der Mischung werden Tabletten gepreßt.
Tablettengewicht: 300 mg
Stempel: 10 mm, flachThe mixed with lactose, corn starch and silica active substance is moistened with a 20% aqueous Polyvinylpyr rolidonlösung and beaten through a sieve with 1.5 mm Ma mesh size.
The granules dried at 45 ° C are again rubbed through the same sieve and mixed with the stated amount of magnesium stearate. From the mixture tablets are pressed.
Tablet weight: 300 mg
Stamp: 10 mm, flat
Der Wirkstoff wird mit den Hilfsstoffen vermengt, durch ein
Sieb von 0,75 mm-Maschenweite gegeben und in einem geeigneten
Gerät homogen gemischt.
Die Endmischung wird in Hartgelatine-Kapseln der Größe 1 ab
gefüllt.
Kapselfüllung: ca. 320 mg
Kapselhülle: Hartgelatine-Kapsel Größe 1.The active ingredient is mixed with the excipients, passed through a sieve of 0.75 mm mesh size and mixed homogeneously in a suitable device.
The final mixture is filled into hard gelatin capsules of size 1.
Capsule filling: approx. 320 mg
Capsule shell: hard gelatin capsule size 1.
Nach dem Aufschmelzen der Suppositorienmasse wird der Wirkstoff darin homogen verteilt und die Schmelze in vorgekühlte Formen gegossen.After melting the suppository mass of the Active substance homogeneously distributed in it and the melt in poured precooled molds.
Dest. Wasser wird auf 70°C erhitzt. Hierin wird unter Rühren
p-Hydroxybenzoesäuremethylester und -propylester sowie
Glycerin und Carboxymethylcellulose-Natriumsalz gelöst. Es
witd auf Raumtemperatur abgekühlt und unter Rühren der
Wirkstoff zugegeben und homogen dispergiert. Nach Zugabe und
Lösen des Zuckers, der Sorbitlösung und des Aromas wird die
Suspension zur Entlüftung unter Rühren evakuiert.
5 ml Suspension enthalten 50 mg Wirkstoff.Dest. Water is heated to 70 ° C. Herein, p-hydroxybenzoic acid methyl ester and propyl ester and glycerol and carboxymethyl cellulose sodium salt are dissolved with stirring. It witd cooled to room temperature and added with stirring, the active ingredient and dispersed homogeneously. After addition and dissolution of the sugar, the sorbitol solution and the aroma, the suspension is evacuated to vent with stirring.
5 ml of suspension contain 50 mg of active ingredient.
Die Wirksubstanz wird in der erforderlichen Menge 0,01 N HCl gelöst, mit Kochsalz isotonisch gestellt, sterilfiltriert und in 2 ml Ampullen abgefüllt. The active substance is in the required amount 0.01 N HCl dissolved, isotonic with saline, sterile filtered and bottled in 2 ml ampoules.
Die Wirksubstanz wird in der erforderlichen Menge 0,01N HCl gelöst, mit Kochsalz isotonisch gestellt, sterilfiltriert und in 10 ml Ampullen abgefüllt.The active substance is added in the required amount of 0.01N HCl dissolved, isotonic with saline, sterile filtered and filled in 10 ml ampoules.
Die Wirksubstanz wird mit Lactose für Inhalationszwecke
gemischt. Die Mischung wird auf einer Kapselmaschine in
Kapseln (Gewicht der Leerkapsel ca. 50 mg) abgefüllt.
Kapselgewicht: 70,0 mg
Kapselgröße: 3
The active substance is mixed with lactose for inhalation purposes. The mixture is filled into capsules on a capsule machine (weight of the empty capsule approx. 50 mg).
Capsule weight: 70.0 mg
Capsule size: 3
Die Wirksubstanz und Benzalkoniumchlorid werden in
Ethanol/Wasser (50/50) gelöst. Der pH-Wert der Lösung wird mit
1 N-Salzsäure eingestellt. Die eingestellte Lösung wird
filtriert und in für den Handvernebler geeignete Behälter
(Kartuschen) abgefüllt.
Füllmasse des Behälters: 4,5 gThe active substance and benzalkonium chloride are dissolved in ethanol / water (50/50). The pH of the solution is adjusted with 1 N hydrochloric acid. The adjusted solution is filtered and filled into containers suitable for the hand nebulizer (cartridges).
Fill weight of the container: 4.5 g
Claims (12)
in der
Ra eine Benzyl- oder 1-Phenylethylgruppe oder eine durch die Reste R1 und R2 substituierte Phenylgruppe, wobei
R1 ein Wasserstoff-, Fluor-, Chlor- oder Bromatom, eine Methyl-, Trifluormethyl-, Cyan- oder Ethinylgruppe und
R2 ein Wasserstoff- oder Fluoratom darstellen,
einer der Reste Rb oder Rc eine R3-(CH2)m-O-Gruppe und der andere der Reste Rb oder Rc eine Methoxy-, Cyclobutyloxy-, Cyclopenty loxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclopen tylmethoxygruppe, wobei
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylamino- oder N-(2-Oxo-tetrahydrofuran-4-yl)-ethylaminogruppe,
eine an den Methylengruppen durch eine oder zwei Methyl- oder Ethylgruppen substituierte R4-O-CO-CH2-N-CH2CH2-OH- Gruppe, in der
R4 ein Wasserstoffatom oder eine C1-4-Alkylgruppe darstellt,
oder eine durch eine oder zwei Methyl- oder Ethylgruppen substituierte 2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-(2-{N-(2-hydroxy-2-methyl-prop-1-yl)-N-[(ethoxycarbonyl)- methyl]-amino}-ethoxy)-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin- 4-yl)-ethoxy]-7-methoxy-chinazolin und
4-[(3-Brom-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofuran-4-yl)- N-methyl-amino]-ethoxy}-7-methoxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.1. Bicyclic heterocycles of the general formula
in the
R a represents a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R 1 and R 2 , where
R 1 is a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyano or ethynyl group and
R 2 represents a hydrogen or fluorine atom,
one of the radicals R b or R c is an R 3 - (CH 2 ) m -O group and the other of the radicals R b or R c is a methoxy, cyclobutyloxy, cyclopenty loxy, cyclopropylmethoxy, cyclobutylmethoxy or Cyclopen tylmethoxygruppe , in which
R 3 is an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino or N- (2-oxo-tetrahydrofuran-4-yl) -ethylamino group,
a R 4 -O-CO-CH 2 -N-CH 2 CH 2 -OH group substituted on the methylene groups by one or two methyl or ethyl groups, in which
R 4 represents a hydrogen atom or a C 1-4 alkyl group,
or a substituted by one or two methyl or ethyl groups 2-oxo-morpholin-4-yl group and
m represent the number 2 or 3,
with the proviso mean that the connections
4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl ) - methyl] -amino} -ethoxy) -quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline and
4 - [(3-Bromo-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7-methoxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Ra eine Benzyl- oder 1-Phenylethylgruppe oder eine durch die Reste R1 und R2 substituierte Phenylgruppe, wobei
R1 ein Wasserstoff-, Fluor-, Chlor- oder Bromatom, eine Methyl-, Trifluormethyl-, Cyan- oder Ethinylgruppe und
R2 ein Wasserstoff- oder Fluoratom darstellen,
einer der Reste Rb oder Rc eine R3-(CH2)m-O-Gruppe und der andere der Reste Rb oder Rc eine Methoxy-, Cyclobutyloxy-, Cyclopentyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclopentylmethoxygruppe, wobei
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylamino- oder N-(2-Oxo-tetrahydrofuran-4-yl)-ethylaminogruppe,
eine an den Methylengruppen durch eine oder zwei Methyl- oder Ethylgruppen substituierte R4-O-CO-CH2-N-CH2CH2-OH- Gruppe, in der
R4 ein Wasserstoffatom oder eine C1-4-Alkylgruppe darstellt,
oder eine durch eine oder zwei Methyl- oder Ethylgruppen substituierte 2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-(2-{N-(2-hydroxy-2-methyl-prop-1-yl)-N-[(ethoxycarbonyl)- methyl]-amino}-ethoxy)-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin- 4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofuran-4-yl)- N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-(2-{N-(2-hydroxy-2-methyl-prop- 1-yl)-N-[(ethoxycarbonyl)methyl]-amino}-ethoxy)-7-methoxy- chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(3-methyl-2-oxo-morpholin- 4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(5,5-dimethyl-2-oxo-morpholin- 4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentyloxy-china zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentylmethoxy- chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy)-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-cyclopentylmethoxy-chinazolin,
(R)-4-[(1-Phenyl-ethyl)amino]-6-[3-(6,6-dimethyl-2-oxo-morpho lin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentyloxy-china zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentylmethoxy- chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-6-cyclopentylmethoxy-chinazolin und
(R)-4-[(1-Phenyl-ethyl)amino]-7-[3-(6,6-dimethyl-2-oxo-morpho lin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.2. Compounds of general formula I according to claim 1, in which
R a represents a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R 1 and R 2 , where
R 1 is a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyano or ethynyl group and
R 2 represents a hydrogen or fluorine atom,
one of R b or R c is an R 3 - (CH 2 ) m -O group and the other of R b or R c is a methoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group, wherein
R 3 is an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino or N- (2-oxo-tetrahydrofuran-4-yl) -ethylamino group,
one at the methylene groups by one or two methyl or ethyl groups substituted R 4 -O-C O -CH 2 -N-CH 2 CH 2 -OH group, in which
R 4 represents a hydrogen atom or a C 1-4 alkyl group,
or a substituted by one or two methyl or ethyl groups 2-oxo-morpholin-4-yl group and
m represent the number 2 or 3,
with the proviso that the compounds are 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- (2- {N- (2-hydroxy-2-methyl-prop-1-) yl) -N - [(ethoxycarbonyl) -methyl] -amino} -ethoxy) -quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl) -methyl] -amino} -ethoxy ) -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy) -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentylmethoxy-quinazoline,
(R) -4 - [(1-phenyl-ethyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentylmethoxy-quinazoline and
(R) -4 - [(1-phenyl-ethyl) -amino] -7- [3- (6,6-dimethyl-2-oxo-morpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Ra eine 1-Phenylethylgruppe oder eine durch die Reste R1 und R2 substituierte Phenylgruppe darstellt, wobei
R1 ein Fluor-, Chlor- oder Bromatom, eine Methyl- oder Ethinylgruppe und
R2 ein Wasserstoff- oder Fluoratom darstellen,
einer der Reste Rb oder Rc eine R3-(CH2)m-O-Gruppe und der andere der Reste Rb oder Rc eine Methoxy-, Cyclobutyloxy-, Cyclo pentyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclopentylmethoxygruppe, wobei
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylaminogruppe,
eine an den Methylengruppen durch eine oder zwei Methyl gruppen substituierte R4-O-CO-CH2-N-CH2CH2-OH-Gruppe, in der
R4 eine C1-4-Alkylgruppe darstellt,
oder eine durch eine oder zwei Methylgruppen substituierte 2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-(2-{N-(2-hydroxy-2-methyl-prop-1-yl)-N-[(ethoxycarbonyl)- methyl]-amino}-ethoxy)-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin- 4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofuran-4-yl)- N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-(2-{N-(2-hydroxy-2-methyl-prop- 1-yl)-N-[(ethoxycarbonyl)methyl]-amino}-ethoxy)-7-methoxy- chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(3-methyl-2-oxo-morpholin- 4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(5,5-dimethyl-2-oxo-morpholin- 4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentyloxy-china zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentylmethoxy- chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-cyclopentylmethoxy-chinazolin,
(R)-4-[(1-Phenyl-ethyl)amino]-6-[3-(6,6-dimethyl-2-oxo-mor- pholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentyloxy-china zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyolopentylmethoxy- chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-1)-propyloxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-6-cyclopentylmethoxy-chinazolin und
(R)-4-[(1-Phenyl-ethyl)amino]-7-[3-(6,6-dimethyl-2-oxo-mor pholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.3. Compounds of general formula I according to claim 1, in which
R a represents a 1-phenylethyl group or a phenyl group substituted by the radicals R 1 and R 2 , wherein
R 1 is a fluorine, chlorine or bromine atom, a methyl or ethynyl group and
R 2 represents a hydrogen or fluorine atom,
one of R b or R c is an R 3 - (CH 2 ) m -O group and the other of R b or R c is a methoxy, cyclobutyloxy, cyclo pentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group, in which
R 3 is an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino group,
a substituted on the methylene groups by one or two methyl groups R 4 -O-CO-CH 2 -N-CH 2 CH 2 -OH group, in which
R 4 represents a C 1-4 alkyl group,
or a substituted by one or two methyl groups 2-oxo-morpholin-4-yl group and
m represent the number 2 or 3,
with the proviso mean that the connections
4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl ) - methyl] -amino} -ethoxy) -quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- (2- {N- (2-hydroxy-2-methyl-prop-1-yl) -N - [(ethoxycarbonyl) -methyl] -amino} -ethoxy ) -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentylmethoxy-quinazoline,
(R) -4 - [(1-phenyl-ethyl) -amino] -6- [3- (6,6-dimethyl-2-oxo-morpholino-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline .
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cylopentyl methoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholine-4-1) -propyloxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentylmethoxy-quinazoline and
(R) -4 - [(1-Phenylethyl) amino] -7- [3- (6,6-dimethyl-2-oxo-morpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Ra eine 1-Phenylethylgruppe oder eine durch die Reste R1 und R2 substituierte Phenylgruppe darstellt, wobei
R1 ein Fluor-, Chlor- oder Bromatom und
R2 ein Wasserstoff- oder Fluoratom darstellen,
einer der Reste Rb oder Rc eine R3-(CH2)m-O-Gruppe und der andere der Reste Rb oder Rc eine Methoxy-, Cyclobutyloxy-, Cyclopen tyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclo pentylmethoxygruppe, wobei
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylaminogruppe oder eine durch eine oder zwei Methylgruppen substituierte 2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin- 4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofuran-4-yl)- N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(3-methyl-2-oxo-morpholin-4-yl)- ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(5,5-dimethyl-2-oxo-morpholin- 4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentyloxy-china zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-{2-[N-(2-oxo-tetrahydrofu ran-4-yl)-N-methyl-amino]-ethoxy}-7-cyclopentylmethoxy-china zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-cyclopentylmethoxy-chinazolin,
(R)-4-[(1-Phenyl-ethyl)amino]-6-[3-(6,6-dimethyl-2-oxo-mor pholin-4-yl)-propyloxy]-7-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentyloxy-china zolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentylmethoxy- chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-6-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-6-cyclopentylmethoxy-chinazolin und
(R)-4-[(1-Phenyl-ethyl)amino]-7-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxyl-6-cyclopentyloxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.4. Compounds of general formula I according to claim 1, in which
R a represents a 1-phenylethyl group or a phenyl group substituted by the radicals R 1 and R 2 , wherein
R 1 is a fluorine, chlorine or bromine atom and
R 2 represents a hydrogen or fluorine atom,
one of the radicals R b or R c is an R 3 - (CH 2 ) m -O group and the other of the radicals R b or R c is a methoxy, cyclobutyloxy, Cyclopen tyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclo pentylmethoxy , in which
R 3 represents an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino group or a 2-oxo-morpholin-4-yl group substituted by one or two methyl groups and
m represent the number 2 or 3,
with the proviso mean that the connections
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} -7- cyclopentylmethoxy-china zoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-cyclopentylmethoxy-quinazoline,
(R) -4 - [(1-phenyl-ethyl) amino] -6- [3- (6,6-dimethyl-2-oxo-morpholin-4-yl) -propyloxy] -7-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentyloxy-china zolin,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentylmethoxy quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -6-cyclopentylmethoxy-quinazoline and
(R) -4 - [(1-Phenylethyl) amino] -7- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy-6-cyclopentyloxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Ra eine 1-Phenylethyl-, 3-Bromphenyl- oder 3-Chlor-4-fluor phenylgruppe,
Rb eine R3-(CH2)m-O-Gruppe, in der
R3 eine durch eine oder zwei Methylgruppen substituierte 2-Oxo-morpholin-4-yl-Gruppe und
m die Zahl 2 oder 3 darstellen,
und Rc eine Methoxy-, Cyclobutyloxy- oder Cyclopropylmethoxy gruppe mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Brom-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo-morpholin- 4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(3-methyl-2-oxo-morpholin- 4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Brom-phenyl)amino]-6-[2-(5,5-dimethyl-2-oxo-morpholin- 4-yl)ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclobutyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-7-cyclopropylmethoxy-chinazolin und
4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-(6,6-dimethyl-2-oxo- morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.5. Compounds of general formula I according to claim 1, in which
R a represents a 1-phenylethyl, 3-bromophenyl or 3-chloro-4-fluorophenyl group,
R b is an R 3 - (CH 2 ) m -O- group in which
R 3 is a substituted by one or two methyl groups 2-oxo-morpholin-4-yl group and
m represent the number 2 or 3,
and R c is a methoxy, cyclobutyloxy or cyclopropylmethoxy group with the proviso that the compounds
4 - [(3-Bromo-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (3-methyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-Bromo-phenyl) -amino] -6- [2- (5,5-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-methoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclobutyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -7-cyclopropylmethoxy-quinazoline and
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3- (6,6-dimethyl-2-oxomorpholin-4-yl) -propyloxy] -7-methoxy-quinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
Ra eine 3-Chlor-4-fluor-phenylgruppe,
Rb eine Cyclopentyloxy-, Cyclopropylmethoxy- oder Cyclopentyl methoxygruppe und
Rc eine R3-(CH2)m-O-Gruppe, in der
R3 eine N-(2-Oxo-tetrahydrofuran-4-yl)-methylaminogruppe oder eine durch zwei Methylgruppen substituierte 2-Oxo morpholin-4-yl-Gruppe und
m die Zahl 2 darstellen,
mit der Maßgabe bedeuten, dass die Verbindungen
4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-[2-(6,6-dimethyl-2-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino)-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopentyloxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopropylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl]amino]-7-[2-(6,6-dimethyl-2-oxo- morpholin-4-yl)-ethoxy]-6-cyclopentylmethoxy-chinazolin,
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentyloxy-china zolin und
4-[(3-Chlor-4-fluor-phenyl)amino]-7-{2-[N-(2-oxo-tetrahydro furan-4-yl)-N-methyl-amino]-ethoxy}-6-cyclopentylmethoxy- chinazolin
ausgeschlossen sind,
deren Tautomeren, deren Stereoisomere und deren Salze.6. Compounds of general formula I according to claim 1, in which
R a is a 3-chloro-4-fluoro-phenyl group,
R b is a cyclopentyloxy, cyclopropylmethoxy or cyclopentyl methoxy group and
R c is an R 3 - (CH 2 ) m -O- group in which
R 3 represents an N- (2-oxo-tetrahydrofuran-4-yl) -methylamino group or a 2-oxo-morpholin-4-yl group substituted by two methyl groups;
m represent the number 2,
with the proviso mean that the connections
4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino) -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentyloxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopropylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- [2- (6,6-dimethyl-2-oxomorpholin-4-yl) -ethoxy] -6-cyclopentylmethoxy-quinazoline,
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentyloxy-china zolin and
4 - [(3-chloro-4-fluoro-phenyl) -amino] -7- {2- [N- (2-oxo-tetrahydro-furan-4-yl) -N-methyl-amino] -ethoxy} -6- cyclopentylmethoxyquinazoline
excluded are,
their tautomers, their stereoisomers and their salts.
(1) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentylmethoxy- 7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
(2) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopentyloxy- 7-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-N-methyl-amino]-ethoxy}- chinazolin,
(3) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy- 7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-chinazolin,
(4) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclobutyloxy- 6-[3-(2,2-dimethyl-6-oxo-morpholin-4-yl)-propyloxy]-china zolin,
(5) 4-[(3-Chlor-4-fluor-phenyl)amino]-7-cyclopropylmethoxy- 6-[3-(2,2-dimethyl-6-oxo-morpholin-4-yl)-propyloxy]-china zolin,
(7) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-cyclopropylmethoxy- 7-{2-[N-(2-oxo-tetrahydrofuran-4-yl)-N-methyl-amino]-ethoxy}- chinazolin,
(8) 4-[(3-Brom-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpho lin-4-yl)-ethoxy]-7-methoxy-chinazolin,
(9) 4-[(3-Brom-phenyl)amino]-6-[2-((R)-6-methyl-2-oxo-morpho lin-4-yl)-ethoxy]-7-methoxy-chinazolin,
(10) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[2-((R)-6-methyl- 2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
(11) 4-[(3-Chlor-4-fluor-phenyl)amino]-6-[3-((R)-6-methyl- 2-oxo-morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin,
(12) 4-[(R)-(1-Phenyl-ethyl)amino]-6-[3-((S)-6-methyl-2-oxo- morpholin-4-yl)-propyloxy]-7-methoxy-chinazolin und
(13) 4-[(R)-(1-Phenyl-ethyl)amino]-6-[2-((S)-6-methyl-2-oxo- morpholin-4-yl)-ethoxy]-7-methoxy-chinazolin,
deren Tautomeren, deren Stereoisomere und deren Salze.7. The following compounds of general formula I according to claim 1:
(1) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentylmethoxy-7- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] - quinazoline,
(2) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopentyloxy-7- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} - quinazoline,
(3) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6-cyclopropylmethoxy-7- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] - quinazoline,
(4) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -7-cyclobutyloxy-6- [3- (2,2-dimethyl-6-oxo-morpholin-4-yl) -propyloxy] - china zolin,
(5) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -7-cyclopropylmethoxy-6- [3- (2,2-dimethyl-6-oxomorpholin-4-yl) -propyloxy] - china zolin,
(7) 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6-cyclopropylmethoxy-7- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl-amino] -ethoxy} - quinazoline,
(8) 4 - [(3-Bromo-phenyl) -amino] -6- [2 - ((S) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline .
(9) 4 - [(3-Bromo-phenyl) -amino] -6- [2 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline .
(10) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7- methoxy-quinazoline,
(11) 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [3 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -propyloxy] -7- methoxy-quinazoline,
(12) 4 - [(R) - (1-phenylethyl) amino] -6- [3 - ((S) -6-methyl-2-oxomorpholin-4-yl) -propyloxy] -7- methoxy-quinazoline and
(13) 4 - [(R) - (1-phenylethyl) amino] -6- [2 - ((S) -6-methyl-2-oxomorpholin-4-yl) -ethoxy] -7- methoxy-quinazoline,
their tautomers, their stereoisomers and their salts.
- a) eine Verbindung der allgemeinen Formel
in der
Ra wie in den Ansprüchen 1 bis 7 erwähnt definiert ist, einer der Reste Rb' oder Rc' eine Methoxy-, Cyclobutyloxy-, Cyclopentyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclopentylmethoxygruppe darstellt und
der andere der Reste Rb' oder Rc' eine Z1-(CH2)m-O-Gruppe dar stellt, in der
m wie in den Ansprüchen 1 bis 7 erwähnt definiert ist und
Z1 eine Austrittsgruppe bedeutet,
mit einer Verbindung der allgemeinen Formel
H - R3, (III)
in der
R3 wie in den Ansprüchen 1 bis 7 erwähnt definiert ist, umgesetzt wird oder - b) eine gegebenenfalls im Reaktionsgemisch gebildete Verbin
dung der allgemeinen Formel
in der
Ra wie in den Ansprüchen 1 bis 7 erwähnt definiert ist, einer der Reste Rb'' oder Rc'' eine Methoxy-, Cyclobutyloxy-, Cyclopentyloxy-, Cyclopropylmethoxy-, Cyclobutylmethoxy- oder Cyclopentylmethoxygruppe darstellt und
der andere der Reste Rb'' oder Rc'' eine R3'-(CH2)m-O-Gruppe dar stellt, in der
m wie in den Ansprüchen 1 bis 7 erwähnt definiert ist und
R3' eine an den Methylengruppen durch eine oder zwei Methyl- oder Ethylgruppen substituierte R4-O-CO-CH2-N-CH2CH2-OH-Gruppe bedeutet, in der
R4 ein Wasserstoffatom oder eine C1-4-Alkylgruppe dar stellt,
cyclisiert wird und
erforderlichenfalls ein bei den vorstehend beschriebenen Umsetzungen verwendeter Schutzrest wieder abgespalten wird und/oder
gewünschtenfalls eine so erhaltene Verbindung der allgemeinen Formel I in ihre Stereoisomere aufgetrennt wird und/oder
eine so erhaltene Verbindung der allgemeinen Formel I in ihre Salze, insbesondere für die pharmazeutische Anwendung in ihre physiologisch verträglichen Salze übergeführt wird.
- a) a compound of the general formula
in the
R a is as defined in claims 1 to 7, one of R b 'or R c ' represents a methoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group and
the other of R b 'or R c ' represents a Z 1 - (CH 2 ) m -O- group in which
m as defined in claims 1 to 7 mentioned and
Z 1 denotes a leaving group,
with a compound of the general formula
H - R 3 , (III)
in the
R 3 is defined as defined in claims 1 to 7, or is reacted - b) an optionally formed in the reaction mixture connec tion of the general formula
in the
R a is as defined in claims 1 to 7, one of R b "or R c " represents a methoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group and
the other of R b "or R c " represents an R 3 '- (CH 2 ) m -O- group in which
m as defined in claims 1 to 7 mentioned and
R 3 'represents a R 4 -O-CO-CH 2 -N-CH 2 CH 2 -OH group substituted on the methylene groups by one or two methyl or ethyl groups, in which
R 4 represents a hydrogen atom or a C 1-4 alkyl group,
is cyclized and
if necessary, a protective moiety used in the reactions described above is split off again and / or
if desired, a compound of general formula I thus obtained is separated into its stereoisomers and / or
a compound of the general formula I thus obtained is converted into its salts, in particular for the pharmaceutical application, into its physiologically tolerated salts.
Priority Applications (34)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10042058A DE10042058A1 (en) | 2000-08-26 | 2000-08-26 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
CNB01814635XA CN100404517C (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
CZ20030870A CZ302567B6 (en) | 2000-08-26 | 2001-08-18 | Aminoquinazolines, pharmaceutical composition containing thereof, the use of the compounds and process for their preparation |
EA200300219A EA005679B1 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
YU14003A RS52279B (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
SK231-2003A SK287747B6 (en) | 2000-08-26 | 2001-08-18 | 4-Aminoquinazolines, method for producing thereof and pharmaceutical compositions containing them |
EP01967285A EP1315705A1 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
IL15460201A IL154602A0 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
UA2003032533A UA73004C2 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles and medicament based thereon |
KR1020037002744A KR100862873B1 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, and methods for the production thereof |
JP2002523469A JP4834282B2 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycle, pharmaceutical composition containing the same, use thereof and method for producing the same |
CA002417897A CA2417897C (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
HU0300819A HUP0300819A3 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
EEP200300077A EE05269B1 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation |
AU2001287694A AU2001287694B2 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
MEP-587/08A MEP58708A (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
BR0113519-8A BR0113519A (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation |
PCT/EP2001/009532 WO2002018351A1 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
PL36024801A PL360248A1 (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
NZ524668A NZ524668A (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use, and processes for preparing them. |
AU8769401A AU8769401A (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
MXPA03001483A MXPA03001483A (en) | 2000-08-26 | 2001-08-18 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof. |
US09/934,772 US6656946B2 (en) | 2000-08-26 | 2001-08-22 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
UY26903A UY26903A1 (en) | 2000-08-26 | 2001-08-23 | BICYCLIC HETEROCICLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION |
TW090120905A TWI294422B (en) | 2000-08-26 | 2001-08-24 | Bicyclic heteocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
MYPI20013985A MY126132A (en) | 2000-08-26 | 2001-08-24 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
ARP010104041A AR033562A1 (en) | 2000-08-26 | 2001-08-24 | BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION |
EC2003004464A ECSP034464A (en) | 2000-08-26 | 2003-02-03 | BICYCLIC HETEROCICLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION |
ZA200300991A ZA200300991B (en) | 2000-08-26 | 2003-02-05 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof. |
BG107559A BG107559A (en) | 2000-08-26 | 2003-02-14 | Bicyclic heteroycles, medicaments containing these compounds, their use and methods for the production thereof |
HR20030138A HRP20030138A2 (en) | 2000-08-26 | 2003-02-24 | Bicyclic heterocycles, medicaments containing these compound, their use, and methods for the production thereof |
IL154602A IL154602A (en) | 2000-08-26 | 2003-02-24 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
NO20030870A NO324866B1 (en) | 2000-08-26 | 2003-02-25 | Bicyclic heterocycles, drugs containing them, their use in the manufacture of drugs for the treatment of diseases, and methods for the preparation thereof |
HK04100462A HK1057557A1 (en) | 2000-08-26 | 2004-01-21 | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10042058A DE10042058A1 (en) | 2000-08-26 | 2000-08-26 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10042058A1 true DE10042058A1 (en) | 2002-03-07 |
Family
ID=7653945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10042058A Ceased DE10042058A1 (en) | 2000-08-26 | 2000-08-26 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1315705A1 (en) |
JP (1) | JP4834282B2 (en) |
KR (1) | KR100862873B1 (en) |
CN (1) | CN100404517C (en) |
AR (1) | AR033562A1 (en) |
AU (2) | AU2001287694B2 (en) |
BG (1) | BG107559A (en) |
BR (1) | BR0113519A (en) |
CA (1) | CA2417897C (en) |
CZ (1) | CZ302567B6 (en) |
DE (1) | DE10042058A1 (en) |
EA (1) | EA005679B1 (en) |
EC (1) | ECSP034464A (en) |
EE (1) | EE05269B1 (en) |
HK (1) | HK1057557A1 (en) |
HR (1) | HRP20030138A2 (en) |
HU (1) | HUP0300819A3 (en) |
IL (2) | IL154602A0 (en) |
ME (1) | MEP58708A (en) |
MX (1) | MXPA03001483A (en) |
MY (1) | MY126132A (en) |
NO (1) | NO324866B1 (en) |
NZ (1) | NZ524668A (en) |
PL (1) | PL360248A1 (en) |
RS (1) | RS52279B (en) |
SK (1) | SK287747B6 (en) |
TW (1) | TWI294422B (en) |
UA (1) | UA73004C2 (en) |
UY (1) | UY26903A1 (en) |
WO (1) | WO2002018351A1 (en) |
ZA (1) | ZA200300991B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011701A1 (en) * | 2003-07-28 | 2005-02-10 | Boehringer Ingelheim International Gmbh | Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes |
WO2005041973A1 (en) * | 2003-10-30 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
WO2007023073A2 (en) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
US7998949B2 (en) | 2007-02-06 | 2011-08-16 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
US8399461B2 (en) | 2006-11-10 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same |
US8497369B2 (en) | 2008-02-07 | 2013-07-30 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production |
US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01012899A (en) | 1999-06-21 | 2002-07-30 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof. |
DE10042059A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
TWI324597B (en) | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
PL371188A1 (en) * | 2002-03-30 | 2005-06-13 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
DE10214412A1 (en) * | 2002-03-30 | 2003-10-09 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and process for their preparation |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
EP2277867B1 (en) | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
DE10326186A1 (en) * | 2003-06-06 | 2004-12-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
AU2004274227B2 (en) | 2003-09-19 | 2008-04-24 | Astrazeneca Ab | Quinazoline derivatives |
EP2609919A3 (en) | 2003-09-26 | 2014-02-26 | Exelixis, Inc. | c-Met modulators and methods of use |
DE10345875A1 (en) * | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods of preparation |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
CA2599210A1 (en) | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
KR100673775B1 (en) * | 2005-04-08 | 2007-01-24 | 엘지전자 주식회사 | Home bar door of refrigerator |
WO2007054550A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
WO2007101782A1 (en) * | 2006-03-09 | 2007-09-13 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them |
EP2068880B1 (en) | 2006-09-18 | 2012-04-11 | Boehringer Ingelheim International GmbH | Method for treating cancer harboring egfr mutations |
JP5739802B2 (en) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | 4- (3-Chloro-2-fluoroanilino) -7-methoxy-6-{[1- (N-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline fumarate |
TWI577664B (en) | 2009-01-16 | 2017-04-11 | 艾克塞里克斯公司 | Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, pharmaceutical composition comprising the same and use thereof |
EP2451445B1 (en) | 2009-07-06 | 2019-04-03 | Boehringer Ingelheim International GmbH | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
UA108618C2 (en) | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
KR101317809B1 (en) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
KR20140096571A (en) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one |
LT2964638T (en) | 2013-03-06 | 2017-12-27 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
PT3126354T (en) * | 2014-04-04 | 2020-03-17 | H Lundbeck As | Halogenated quinazolin-thf-amines as pde1 inhibitors |
US20170176028A1 (en) | 2015-12-18 | 2017-06-22 | Lg Electronics Inc. | Air conditioner |
CN110291104B (en) | 2016-11-17 | 2023-11-03 | 得克萨斯州大学***董事会 | Compounds having anti-tumor activity against cancer cells harboring EGFR or HER2 exon 20 mutations |
CN112321814B (en) * | 2020-12-30 | 2021-03-23 | 广州初曲科技有限公司 | Preparation and application of gefitinib idebenone conjugate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6184225B1 (en) * | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
DE69709319T2 (en) * | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-ANILINOQUINAZOLINE DERIVATIVES |
BR9708640B1 (en) * | 1996-04-12 | 2013-06-11 | irreversible tyrosine kinase inhibitors and pharmaceutical composition comprising them. | |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
DE19911509A1 (en) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
-
2000
- 2000-08-26 DE DE10042058A patent/DE10042058A1/en not_active Ceased
-
2001
- 2001-08-18 EA EA200300219A patent/EA005679B1/en not_active IP Right Cessation
- 2001-08-18 CZ CZ20030870A patent/CZ302567B6/en not_active IP Right Cessation
- 2001-08-18 ME MEP-587/08A patent/MEP58708A/en unknown
- 2001-08-18 KR KR1020037002744A patent/KR100862873B1/en not_active IP Right Cessation
- 2001-08-18 UA UA2003032533A patent/UA73004C2/en unknown
- 2001-08-18 CA CA002417897A patent/CA2417897C/en not_active Expired - Fee Related
- 2001-08-18 CN CNB01814635XA patent/CN100404517C/en not_active Expired - Fee Related
- 2001-08-18 NZ NZ524668A patent/NZ524668A/en not_active IP Right Cessation
- 2001-08-18 MX MXPA03001483A patent/MXPA03001483A/en active IP Right Grant
- 2001-08-18 HU HU0300819A patent/HUP0300819A3/en unknown
- 2001-08-18 EP EP01967285A patent/EP1315705A1/en not_active Ceased
- 2001-08-18 PL PL36024801A patent/PL360248A1/en not_active Application Discontinuation
- 2001-08-18 BR BR0113519-8A patent/BR0113519A/en active Pending
- 2001-08-18 AU AU2001287694A patent/AU2001287694B2/en not_active Ceased
- 2001-08-18 AU AU8769401A patent/AU8769401A/en active Pending
- 2001-08-18 JP JP2002523469A patent/JP4834282B2/en not_active Expired - Fee Related
- 2001-08-18 SK SK231-2003A patent/SK287747B6/en not_active IP Right Cessation
- 2001-08-18 RS YU14003A patent/RS52279B/en unknown
- 2001-08-18 WO PCT/EP2001/009532 patent/WO2002018351A1/en active Application Filing
- 2001-08-18 IL IL15460201A patent/IL154602A0/en unknown
- 2001-08-18 EE EEP200300077A patent/EE05269B1/en not_active IP Right Cessation
- 2001-08-23 UY UY26903A patent/UY26903A1/en not_active Application Discontinuation
- 2001-08-24 TW TW090120905A patent/TWI294422B/en not_active IP Right Cessation
- 2001-08-24 MY MYPI20013985A patent/MY126132A/en unknown
- 2001-08-24 AR ARP010104041A patent/AR033562A1/en not_active Suspension/Interruption
-
2003
- 2003-02-03 EC EC2003004464A patent/ECSP034464A/en unknown
- 2003-02-05 ZA ZA200300991A patent/ZA200300991B/en unknown
- 2003-02-14 BG BG107559A patent/BG107559A/en active Pending
- 2003-02-24 HR HR20030138A patent/HRP20030138A2/en not_active Application Discontinuation
- 2003-02-24 IL IL154602A patent/IL154602A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030870A patent/NO324866B1/en not_active IP Right Cessation
-
2004
- 2004-01-21 HK HK04100462A patent/HK1057557A1/en not_active IP Right Cessation
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011701A1 (en) * | 2003-07-28 | 2005-02-10 | Boehringer Ingelheim International Gmbh | Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes |
WO2005041973A1 (en) * | 2003-10-30 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
WO2007023073A2 (en) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
WO2007023073A3 (en) * | 2005-08-22 | 2007-05-18 | Boehringer Ingelheim Int | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
US8399461B2 (en) | 2006-11-10 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same |
US7998949B2 (en) | 2007-02-06 | 2011-08-16 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
US8497369B2 (en) | 2008-02-07 | 2013-07-30 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production |
US8772298B2 (en) | 2008-02-07 | 2014-07-08 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production |
US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10042058A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | |
EP1315718B1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
EP1731511B1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | |
EP1315720B1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
DE60022866T2 (en) | BICYCLIC HETEROCYCLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | |
EP1345910B9 (en) | Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof | |
EP1280798B1 (en) | Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them | |
DE10042060A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | |
EP1597240B1 (en) | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof | |
DE10042061A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | |
EP1921070A1 (en) | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation | |
DE10326186A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | |
EP2118075A1 (en) | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof | |
DE10042064A1 (en) | Chinazolines, medicaments containing these compounds, their use and processes for their preparation | |
DE10214412A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and process for their preparation | |
DE19908567A1 (en) | New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases | |
DE19911366A1 (en) | New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases | |
DE19928281A1 (en) | Arylamino and aralkylamino substituted quinoline and quinazoline derivatives, useful for the treatment of e.g. tumors, pulmonary, respiratory and gastrointestinal disorders and psoriasis | |
DE19928306A1 (en) | New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases | |
DE10023085A1 (en) | Arylamino and aralkylamino substituted quinoline and quinazoline derivatives, useful for the treatment of e.g. tumors, pulmonary, respiratory and gastrointestinal disorders and psoriasis | |
DE19954816A1 (en) | New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8127 | New person/name/address of the applicant |
Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG, 55218 IN |
|
8110 | Request for examination paragraph 44 | ||
R002 | Refusal decision in examination/registration proceedings | ||
R003 | Refusal decision now final |
Effective date: 20130528 |